
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Regulation of cisplatin resistance in lung cancer by epigenetic mechanisms - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="D2E4AF058AF3143305AF05004F2DBF16.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="clinepig">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12376372/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Clinical Epigenetics">
<meta name="citation_title" content="Regulation of cisplatin resistance in lung cancer by epigenetic mechanisms">
<meta name="citation_author" content="Xiaoyan Yu">
<meta name="citation_author_institution" content="The Second Clinical Medical College of Guangzhou, University of Chinese Medicine, Guangzhou, Guangdong 510120 People’s Republic of China">
<meta name="citation_author" content="Luyu Jia">
<meta name="citation_author_institution" content="The Second Clinical Medical College of Guangzhou, University of Chinese Medicine, Guangzhou, Guangdong 510120 People’s Republic of China">
<meta name="citation_author" content="Qing Tang">
<meta name="citation_author_institution" content="Clinical and Basic Research Team of TCM Prevention and Treatment of NSCLC, Department of Oncology, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Chinese Medicine Guangdong Laboratory, State Key Laboratory of Traditional Chinese Medicine Syndrome, Guangdong Provincial Key Laboratory of Clinical Research On Traditional Chinese Medicine Syndrome, Guangzhou, 510120 Guangdong China">
<meta name="citation_author" content="Qichun Zhou">
<meta name="citation_author_institution" content="Clinical and Basic Research Team of TCM Prevention and Treatment of NSCLC, Department of Oncology, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Chinese Medicine Guangdong Laboratory, State Key Laboratory of Traditional Chinese Medicine Syndrome, Guangdong Provincial Key Laboratory of Clinical Research On Traditional Chinese Medicine Syndrome, Guangzhou, 510120 Guangdong China">
<meta name="citation_author" content="Genshu Wang">
<meta name="citation_author_institution" content="State Key Laboratory of Traditional Chinese Medicine Syndrome; Department of Liver transplant and Surgery of Guangdong Provincial Hospital of Chinese Medicine, Guangdong Provincial Engineering Research Center of Precicion Intelligent Surgical Equipment, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China">
<meta name="citation_author" content="Sumei Wang">
<meta name="citation_author_institution" content="Clinical and Basic Research Team of TCM Prevention and Treatment of NSCLC, Department of Oncology, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Chinese Medicine Guangdong Laboratory, State Key Laboratory of Traditional Chinese Medicine Syndrome, Guangdong Provincial Key Laboratory of Clinical Research On Traditional Chinese Medicine Syndrome, Guangzhou, 510120 Guangdong China">
<meta name="citation_publication_date" content="2025 Aug 24">
<meta name="citation_volume" content="17">
<meta name="citation_firstpage" content="145">
<meta name="citation_doi" content="10.1186/s13148-025-01961-6">
<meta name="citation_pmid" content="40851017">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12376372/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12376372/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12376372/pdf/13148_2025_Article_1961.pdf">
<meta name="description" content="Lung cancer remains one of the most prevalent and lethal malignancies worldwide, responsible for nearly 1.8 million deaths annually, which accounts for approximately 18.7% of global cancer-related mortality. Cisplatin, a highly effective and widely ...">
<meta name="og:title" content="Regulation of cisplatin resistance in lung cancer by epigenetic mechanisms">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Lung cancer remains one of the most prevalent and lethal malignancies worldwide, responsible for nearly 1.8 million deaths annually, which accounts for approximately 18.7% of global cancer-related mortality. Cisplatin, a highly effective and widely ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12376372/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12376372">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1186/s13148-025-01961-6"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/13148_2025_Article_1961.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12376372%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12376372/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12376372/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12376372/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-clinepig.png" alt="Clinical Epigenetics logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Clinical Epigenetics" title="Link to Clinical Epigenetics" shape="default" href="https://clinicalepigeneticsjournal.biomedcentral.com/" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Clin Epigenetics</button></div>. 2025 Aug 24;17:145. doi: <a href="https://doi.org/10.1186/s13148-025-01961-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1186/s13148-025-01961-6</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22Clin%20Epigenetics%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Clin%20Epigenetics%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Clin%20Epigenetics%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Clin%20Epigenetics%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Regulation of cisplatin resistance in lung cancer by epigenetic mechanisms</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Yu%20X%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Xiaoyan Yu</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Xiaoyan Yu</span></h3>
<div class="p">
<sup>1</sup>The Second Clinical Medical College of Guangzhou, University of Chinese Medicine, Guangzhou, Guangdong 510120 People’s Republic of China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Yu%20X%22%5BAuthor%5D" class="usa-link"><span class="name western">Xiaoyan Yu</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Jia%20L%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Luyu Jia</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Luyu Jia</span></h3>
<div class="p">
<sup>1</sup>The Second Clinical Medical College of Guangzhou, University of Chinese Medicine, Guangzhou, Guangdong 510120 People’s Republic of China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Jia%20L%22%5BAuthor%5D" class="usa-link"><span class="name western">Luyu Jia</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Tang%20Q%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Qing Tang</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Qing Tang</span></h3>
<div class="p">
<sup>2</sup>Clinical and Basic Research Team of TCM Prevention and Treatment of NSCLC, Department of Oncology, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Chinese Medicine Guangdong Laboratory, State Key Laboratory of Traditional Chinese Medicine Syndrome, Guangdong Provincial Key Laboratory of Clinical Research On Traditional Chinese Medicine Syndrome, Guangzhou, 510120 Guangdong China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Tang%20Q%22%5BAuthor%5D" class="usa-link"><span class="name western">Qing Tang</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhou%20Q%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Qichun Zhou</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Qichun Zhou</span></h3>
<div class="p">
<sup>2</sup>Clinical and Basic Research Team of TCM Prevention and Treatment of NSCLC, Department of Oncology, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Chinese Medicine Guangdong Laboratory, State Key Laboratory of Traditional Chinese Medicine Syndrome, Guangdong Provincial Key Laboratory of Clinical Research On Traditional Chinese Medicine Syndrome, Guangzhou, 510120 Guangdong China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhou%20Q%22%5BAuthor%5D" class="usa-link"><span class="name western">Qichun Zhou</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wang%20G%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Genshu Wang</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Genshu Wang</span></h3>
<div class="p">
<sup>3</sup> State Key Laboratory of Traditional Chinese Medicine Syndrome; Department of Liver transplant and Surgery of Guangdong Provincial Hospital of Chinese Medicine, Guangdong Provincial Engineering Research Center of Precicion Intelligent Surgical Equipment, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wang%20G%22%5BAuthor%5D" class="usa-link"><span class="name western">Genshu Wang</span></a>
</div>
</div>
<sup>3,</sup><sup>✉</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wang%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Sumei Wang</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Sumei Wang</span></h3>
<div class="p">
<sup>2</sup>Clinical and Basic Research Team of TCM Prevention and Treatment of NSCLC, Department of Oncology, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Chinese Medicine Guangdong Laboratory, State Key Laboratory of Traditional Chinese Medicine Syndrome, Guangdong Provincial Key Laboratory of Clinical Research On Traditional Chinese Medicine Syndrome, Guangzhou, 510120 Guangdong China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wang%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Sumei Wang</span></a>
</div>
</div>
<sup>2,</sup><sup>✉</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="Aff1">
<sup>1</sup>The Second Clinical Medical College of Guangzhou, University of Chinese Medicine, Guangzhou, Guangdong 510120 People’s Republic of China </div>
<div id="Aff2">
<sup>2</sup>Clinical and Basic Research Team of TCM Prevention and Treatment of NSCLC, Department of Oncology, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Chinese Medicine Guangdong Laboratory, State Key Laboratory of Traditional Chinese Medicine Syndrome, Guangdong Provincial Key Laboratory of Clinical Research On Traditional Chinese Medicine Syndrome, Guangzhou, 510120 Guangdong China </div>
<div id="Aff3">
<sup>3</sup> State Key Laboratory of Traditional Chinese Medicine Syndrome; Department of Liver transplant and Surgery of Guangdong Provincial Hospital of Chinese Medicine, Guangdong Provincial Engineering Research Center of Precicion Intelligent Surgical Equipment, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China </div>
<div class="author-notes p"><div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div></div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2025 Mar 21; Accepted 2025 Aug 18; Collection date 2025.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© The Author(s) 2025</div>
<p><strong>Open Access</strong> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <a href="https://creativecommons.org/licenses/by-nc-nd/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by-nc-nd/4.0/</a>.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12376372  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40851017/" class="usa-link">40851017</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="Abs1"><h2>Abstract</h2>
<p id="Par1">Lung cancer remains one of the most prevalent and lethal malignancies worldwide, responsible for nearly 1.8 million deaths annually, which accounts for approximately 18.7% of global cancer-related mortality. Cisplatin, a highly effective and widely utilized anticancer drug, is particularly effective against solid tumors and serves as a cornerstone of adjuvant chemotherapy for lung cancer. Despite continuous optimization of cisplatin-based chemotherapy regimens, the emergence of cisplatin resistance frequently results in treatment failure, significantly limiting its clinical utility and therapeutic efficacy. To address this challenge, researchers have extensively investigated the biological mechanisms underlying cisplatin resistance, including impaired DNA repair pathways and inhibition of apoptosis. Among these mechanisms, epigenetic regulation—encompassing DNA methylation, histone modifications, and noncoding RNA (ncRNA) regulation—has emerged as a critical factor in mediating cisplatin resistance by modulating gene expression and signaling pathways. This review comprehensively explores the role of epigenetic mechanisms in cisplatin resistance in lung cancer, highlighting recent research findings and their potential implications for developing strategies to overcome drug resistance.</p>
<section id="kwd-group1" lang="en" class="kwd-group"><p><strong>Keywords:</strong> Lung cancer, Cisplatin resistance, Epigenetic regulation, DNA methylation, Noncoding RNA</p></section></section><section id="Sec1"><h2 class="pmc_sec_title">Introduction</h2>
<p id="Par2">Lung cancer is one of the most prevalent and deadly malignancies worldwide, with high morbidity and mortality rates primarily attributed to risk factors such as smoking, air pollution, and genetic predisposition. According to recent global statistics, lung cancer accounts for approximately 12.4% of all cancer cases, with nearly 2.5 million new cases diagnosed annually [<a href="#CR1" class="usa-link" aria-describedby="CR1">1</a>]. Lung cancer is broadly classified into two main types: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC, which constitutes about 85% of all lung cancer cases, is the most common form and includes subtypes such as squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. In contrast, SCLC, representing approximately 15% of cases, is less common but more aggressive, often associated with a poorer prognosis [<a href="#CR2" class="usa-link" aria-describedby="CR2">2</a>]. Lung cancer is frequently characterized by an insidious onset, with the majority of NSCLC patients diagnosed at advanced or metastatic stages. Despite significant advancements in cisplatin-based chemotherapy regimens over the past few decades, treatment outcomes remain suboptimal, with a 5-year survival rate of less than 20% [<a href="#CR3" class="usa-link" aria-describedby="CR3">3</a>]. Similarly, although SCLC is initially sensitive to chemotherapy, long-term survival rates remain dismal, with a 5-year survival rate of less than 10%, largely due to its aggressive nature and high recurrence rate [<a href="#CR4" class="usa-link" aria-describedby="CR4">4</a>].</p>
<p id="Par3">Cisplatin-based combination chemotherapy has become a cornerstone of adjuvant treatment for lung cancer patients. The addition of adjuvant chemotherapy in patients with stage II, IIIA, or selected stage IB disease has been shown to improve survival rates by 5–10% [<a href="#CR5" class="usa-link" aria-describedby="CR5">5</a>, <a href="#CR6" class="usa-link" aria-describedby="CR6">6</a>]. Cisplatin, first approved by the United States Food and Drug Administration in 1979, is now one of the most widely used chemotherapy drugs, demonstrating significant clinical efficacy against various cancers, including ovarian, bladder, lung, and head and neck tumors [<a href="#CR7" class="usa-link" aria-describedby="CR7">7</a>]. However, the attenuation of DNA damage-mediated apoptotic signaling represents a major limitation in cisplatin-based chemotherapy, ultimately leading to the development of drug resistance [<a href="#CR8" class="usa-link" aria-describedby="CR8">8</a>]. To mitigate its side effects, alternative platinum-based compounds, such as carboplatin and oxaliplatin, have been developed. These agents offer improved patient tolerance while maintaining anticancer efficacy [<a href="#CR9" class="usa-link" aria-describedby="CR9">9</a>]. Unfortunately, many lung cancer patients exhibit poor initial responses to cisplatin, and even those who initially respond often develop resistance over time. Consequently, cisplatin resistance is a critical factor contributing to treatment failure and poor prognosis in lung cancer patients.</p>
<p id="Par4">Cisplatin resistance is a multifactorial and complex process involving multiple layers of biological regulation. In recent years, significant progress has been made in elucidating the underlying mechanisms of cisplatin resistance in lung cancer cells. Key mechanisms include the abnormal expression of drug transporters, enhanced DNA damage repair capacity, dysregulation of cell cycle control, and inhibition of apoptosis [<a href="#CR10" class="usa-link" aria-describedby="CR10">10</a>]. Additionally, epigenetic modifications—such as DNA methylation, histone modifications, and noncoding RNA regulation—play a pivotal role in cisplatin resistance by altering the expression of critical genes involved in drug sensitivity [<a href="#CR11" class="usa-link" aria-describedby="CR11">11</a>]. For example, epigenetic changes can modulate genes associated with cell cycle regulation, apoptosis, autophagy, and DNA damage repair pathways. Furthermore, epigenetic mechanisms can influence the expression of multidrug resistance-associated proteins, thereby enhancing drug efflux and reducing intracellular drug accumulation [<a href="#CR12" class="usa-link" aria-describedby="CR12">12</a>–<a href="#CR14" class="usa-link" aria-describedby="CR14">14</a>]. A comprehensive understanding of the molecular mechanisms driving cisplatin resistance is essential for developing effective therapeutic strategies. This review focuses on the epigenetic regulatory mechanisms underlying cisplatin resistance in lung cancer, aiming to provide new insights and potential strategies to overcome drug resistance and improve patient outcomes.</p></section><section id="Sec2"><h2 class="pmc_sec_title">Molecular basis of cisplatin anticancer mechanism and drug resistance</h2>
<section id="Sec3"><h3 class="pmc_sec_title">Mechanism of action of cisplatin</h3>
<p id="Par5">Cisplatin, as one of the first metal-based chemotherapy drugs. Chemically known as cis-diamminedichloroplatinum(II), cisplatin is an inorganic metal complex consisting of a platinum atom coordinated with two chlorine atoms and two ammonia molecules, forming a planar square structure (Fig. <a href="#Fig1" class="usa-link">1</a>)[<a href="#CR15" class="usa-link" aria-describedby="CR15">15</a>]. This unique structure makes the cisplatin molecule highly chemically reactive.</p>
<figure class="fig xbox font-sm" id="Fig1"><h4 class="obj_head">Fig. 1.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b628/12376372/b8e5e22c852b/13148_2025_1961_Fig1_HTML.jpg" loading="lazy" id="MO1" height="428" width="597" alt="Fig. 1"></p>
<div class="p text-right font-secondary"><a href="figure/Fig1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Molecular structure of cisplatin</p></figcaption></figure><p id="Par6">Cisplatin, chemically known as cis-diamminedichloroplatinum(II), has the molecular formula Pt(NH<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>. It is composed of one platinum (Pt) atom coordinated with two ammonia (NH<sub>3</sub>) ligands and two chloride (Cl⁻) ions, forming a planar square configuration.</p>
<p id="Par7">Studies have shown that DNA is the primary target of cisplatin’s anticancer activity, and the main cytotoxic effect of cisplatin occurs when it binds to DNA, causing DNA damage that blocks DNA synthesis, halts DNA replication, and activates various signal transduction pathways, ultimately leading to necrosis or apoptosis. These pathways include ATR, p53, MAPK, and others [<a href="#CR16" class="usa-link" aria-describedby="CR16">16</a>, <a href="#CR17" class="usa-link" aria-describedby="CR17">17</a>]. Oxidative stress is also a common effect of cisplatin treatment. Cisplatin can increase the level of oxidative stress in cells by generating reactive oxygen species (ROS), such as hydroxyl radicals and superoxides. These ROS can cause DNA damage, thereby triggering apoptosis [<a href="#CR18" class="usa-link" aria-describedby="CR18">18</a>]. As shown in Fig. <a href="#Fig2" class="usa-link">2</a>, cisplatin binds to DNA to form adducts, inducing DNA damage and subsequent cellular responses.</p>
<figure class="fig xbox font-sm" id="Fig2"><h4 class="obj_head">Fig. 2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12376372_13148_2025_1961_Fig2_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b628/12376372/104a2a8676ea/13148_2025_1961_Fig2_HTML.jpg" loading="lazy" id="MO2" height="608" width="777" alt="Fig. 2"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Cisplatin’s mode of action</p></figcaption></figure><p id="Par8">Cisplatin primarily exerts its cytotoxic effects through the formation of DNA adducts following binding to genomic DNA, which induces DNA damage and disrupts replication processes. This DNA damage subsequently triggers the activation of critical signaling pathways—including the ATR, p53, and MAPK pathways—ultimately resulting in cell cycle arrest, apoptotic cell death, or necrosis. As illustrated in the figure, cisplatin treatment also generates elevated levels of ROS, which synergistically exacerbate DNA damage and potentiate cellular demise. This integrated mechanism provides a comprehensive framework for understanding cisplatin’s cytotoxic activity and its fundamental role in cancer therapeutics. </p>
<p id="Par9">##ATR, Ataxia telangiectasia and Rad3-related kinase; ROS, reactive oxygen species; MAPK, mitogen-activated protein kinase; CHK1, checkpoint kinase 1; CHK2, checkpoint kinase 2; P21, cyclin-dependent kinase inhibitor 1 A; CDK2, cyclin-dependent kinase 2; CDK1, cyclin-dependent kinase 1.</p></section><section id="Sec4"><h3 class="pmc_sec_title">Mechanism of cisplatin resistance</h3>
<p id="Par10">We all know that cisplatin causes DNA damage, which triggers apoptotic signals, but this signal gradually weakens, and the resulting drug resistance problem has become the biggest obstacle to cisplatin treatment for cancer. Platinum-based drug treatments are characterized by both intrinsic and acquired resistance. Intrinsic resistance occurs at the onset of treatment, while acquired resistance develops when the drug is initially effective but gradually becomes less active over time, resulting in resistance [<a href="#CR19" class="usa-link" aria-describedby="CR19">19</a>]. The development of cisplatin resistance in tumor cells is a complex and multifactorial biological phenomenon that involves several molecular mechanisms, such as enhanced DNA repair, apoptotic escape, and increased drug efflux.</p>
<p id="Par11">Recent studies have shown that cisplatin resistance is associated with alterations in DNA repair pathways. DNA damage repair is a crucial pathway by which cells respond to DNA damage, involving mechanisms such as nucleotide excision repair (NER), mismatch repair (MMR), and homologous recombination repair (HRR) [<a href="#CR20" class="usa-link" aria-describedby="CR20">20</a>]. Tumor cells can efficiently recognize and repair cisplatin-induced DNA damage through these repair pathways, restoring cellular function and enabling survival [<a href="#CR21" class="usa-link" aria-describedby="CR21">21</a>]. When they fail to repair DNA damage, cells undergo apoptosis [<a href="#CR22" class="usa-link" aria-describedby="CR22">22</a>]. Studies have shown that cisplatin toxicity can be influenced by interference with DNA repair pathways. For example, cells that overexpress NER are less sensitive to cisplatin [<a href="#CR23" class="usa-link" aria-describedby="CR23">23</a>]. Therefore, tumor cells can reduce cisplatin-induced DNA damage by enhancing these repair pathways, ultimately contributing to drug resistance [<a href="#CR24" class="usa-link" aria-describedby="CR24">24</a>].</p>
<p id="Par12">Decreased drug uptake and increased efflux are key mechanisms by which tumor cells develop resistance to cisplatin. Reduced cisplatin uptake and enhanced efflux result in lower drug accumulation in cancer cells [<a href="#CR25" class="usa-link" aria-describedby="CR25">25</a>]. The copper transporter CTR1 has been shown to be responsible for cisplatin uptake. Cisplatin causes a decrease in CTR1 concentration, which reduces its accumulation in cancer cells and contributes to drug resistance [<a href="#CR26" class="usa-link" aria-describedby="CR26">26</a>, <a href="#CR27" class="usa-link" aria-describedby="CR27">27</a>]. Cells with higher CTR1 expression are more sensitive to cisplatin [<a href="#CR16" class="usa-link" aria-describedby="CR16">16</a>]. Additionally, multidrug resistance (MDR) proteins, such as P- glycoprotein (P-gp), multidrug resistance-associated protein (MRP), and ABC transporters, actively pump a variety of chemotherapy drugs, including cisplatin, out of cells. This reduces drug accumulation and diminishes their efficacy [<a href="#CR28" class="usa-link" aria-describedby="CR28">28</a>]. In addition, the copper transporters ATP7A and ATP7B are also involved in the efflux process of cisplatin and result drug resistance [<a href="#CR29" class="usa-link" aria-describedby="CR29">29</a>].</p>
<p id="Par13">In addition, cisplatin exerts its anti-tumor effects by inducing apoptosis. However, tumor cells can escape apoptosis through various mechanisms, such as upregulating the expression of anti-apoptotic proteins (e.g., Bcl-2, Bcl-xL), downregulating the expression of pro-apoptotic proteins (e.g., Bax, Bak), or activating survival signaling pathways (e.g., PI3K/AKT, MAPK). These processes enable tumor cells to resist cisplatin-induced apoptosis [<a href="#CR30" class="usa-link" aria-describedby="CR30">30</a>–<a href="#CR32" class="usa-link" aria-describedby="CR32">32</a>].</p></section></section><section id="Sec5"><h2 class="pmc_sec_title">Epigenetic modification and cisplatin resistance</h2>
<p id="Par14">Epigenetic modifications refer to changes in the expression and function of genes that regulate without any modification of the DNA sequence, mainly including DNA methylation, histone modifications, and noncoding RNA expression [<a href="#CR33" class="usa-link" aria-describedby="CR33">33</a>]. Compared to stable genetic events, epigenetic changes are highly malleable. Studies have found that epigenetic modifications may contribute to the development of multiple cancer types, which play a crucial role in the occurrence and progression of lung cancer [<a href="#CR34" class="usa-link" aria-describedby="CR34">34</a>, <a href="#CR35" class="usa-link" aria-describedby="CR35">35</a>]. Moreover, there is growing evidence of a clear link between epigenetic modifications and cisplatin resistance in lung cancer [<a href="#CR36" class="usa-link" aria-describedby="CR36">36</a>] (Fig. <a href="#Fig3" class="usa-link">3</a>), for example abnormal DNA methylation status, overexpression or downregulation of microRNAs, etc.</p>
<figure class="fig xbox font-sm" id="Fig3"><h3 class="obj_head">Fig. 3.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12376372_13148_2025_1961_Fig3_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b628/12376372/d253c97735cc/13148_2025_1961_Fig3_HTML.jpg" loading="lazy" id="MO3" height="598" width="777" alt="Fig. 3"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Epigenetic regulation is an important mechanism of cisplatin resistance in lung cancer</p></figcaption></figure><p id="Par15">The figure systematically summarizes several key epigenetic regulatory mechanisms involved in cisplatin resistance in lung cancer. It illustrates the functional roles of DNA methylation, histone modifications, and noncoding RNAs (including miRNAs, lncRNAs, and circRNAs) in modulating gene expression: (1) DNA methylation silences tumor suppressor genes (e.g., NNT, HOXA11); (2) histone modifications (e.g., EZH2-mediated H3K27me3) alter chromatin structure; and (3) noncoding RNAs (miRNAs, lncRNAs, circRNAs) regulate drug efflux and apoptosis pathways. These epigenetic alterations can affect the transcriptional activity of critical genes, thereby influencing cellular processes such as apoptosis, DNA repair, drug uptake, and efflux, ultimately leading to cisplatin resistance.</p>
<p id="Par16">##EZH2, enhancer of zeste homolog 2; ERCC1, excision repair cross-complementation group 1; H3K27me3, trimethylation of histone H3 lysine 27; PD-L1 programmed death-ligand 1; NNT, nicotinamide nucleotide transhydrogenase; HOXA11, homeobox A11; FOXF1, forkhead box F1; MALAT1, metastasis-associated lung adenocarcinoma transcript 1; PUMA, p53 upregulated modulator of apoptosis; JMJD1B, jumonji domain-containing protein 1B; PCNA, proliferating cell nuclear antigen.</p>
<section id="Sec6"><h3 class="pmc_sec_title">DNA methylation</h3>
<p id="Par17">DNA methylation is an important epigenetic modification that affects gene expression, transcription, and activity [<a href="#CR37" class="usa-link" aria-describedby="CR37">37</a>]. This process involves the transfer of methyl groups to the C5 position of cytosine, forming 5-methylcytosine, and is primarily catalyzed by DNA methyltransferases (DNMTs). Hypermethylation of gene promoters often leads to transcriptional repression, resulting in reduced gene expression [<a href="#CR38" class="usa-link" aria-describedby="CR38">38</a>, <a href="#CR39" class="usa-link" aria-describedby="CR39">39</a>]. Aberrant methylation patterns, such as genome-wide hypomethylation and hypermethylation in specific gene promoter regions, are commonly observed in tumors, this indicates that abnormal methylation patterns are involved in the development and progression of tumors [<a href="#CR40" class="usa-link" aria-describedby="CR40">40</a>, <a href="#CR41" class="usa-link" aria-describedby="CR41">41</a>]. In normal cells, however, CpG islands are generally unmethylated [<a href="#CR42" class="usa-link" aria-describedby="CR42">42</a>].</p>
<p id="Par18">Several studies have shown that hypermethylation of DNA is strongly associated with cisplatin resistance [<a href="#CR43" class="usa-link" aria-describedby="CR43">43</a>–<a href="#CR45" class="usa-link" aria-describedby="CR45">45</a>]. Through comprehensive analysis of DNA methylation and mRNA expression profiles, researchers found that DNA methylation levels were significantly higher in cisplatin-resistant tumor samples for NSCLC [<a href="#CR46" class="usa-link" aria-describedby="CR46">46</a>]. Nicotinamide ribotide transhydrogenase (NNT) is a mitochondrial matrixlocalized enzyme [<a href="#CR47" class="usa-link" aria-describedby="CR47">47</a>]. Hypermethylation of tumor suppressor genes such as NNT and HOXA11 leads to their downregulation, promoting cisplatin resistance. For instance, NNT is silenced by DNA hypermethylation in cisplatin-resistant lung cancer cells, which promotes autophagy and cisplatin resistance [<a href="#CR48" class="usa-link" aria-describedby="CR48">48</a>]. Similarly, HOXA11 is hypermethylated and downregulated in cisplatin-resistant cells, while the expression level of HOXA11-AS is increased. HOXA11 is a member of the homeobox (HOX) gene family, HOXA11-AS, an oncogenic long-chain noncoding RNA, which is a natural antisense transcript of HOXA11 [<a href="#CR49" class="usa-link" aria-describedby="CR49">49</a>]. When the HOXA11 gene is knocked down, it induces cisplatin resistance in lung cancer cells; conversely, knocking down the HOXA11-AS gene increases the sensitivity of lung cancer cells to cisplatin. This inverse interaction between HOXA11 and HOXA11-AS promotes the occurrence of cisplatin resistance [<a href="#CR50" class="usa-link" aria-describedby="CR50">50</a>]. Table <a href="#Tab1" class="usa-link">1</a> summarizes the key genes associated with cisplatin resistance through DNA methylation, including NNT, HOXA11, and FOXF1.
</p>
<section class="tw xbox font-sm" id="Tab1"><h4 class="obj_head">Table 1.</h4>
<div class="caption p"><p>DNA methylation genes linked to cisplatin resistance in lung cancer</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">Gene</th>
<th align="left" colspan="1" rowspan="1">DNA methylation status</th>
<th align="left" colspan="1" rowspan="1">Mechanisms of resistance</th>
<th align="left" colspan="1" rowspan="1">References</th>
</tr></thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">NNT</td>
<td align="left" colspan="1" rowspan="1">Hypermethylation</td>
<td align="left" colspan="1" rowspan="1">Inhibits autophagic death</td>
<td align="left" colspan="1" rowspan="1">[<a href="#CR48" class="usa-link" aria-describedby="CR48">48</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">HOXA11</td>
<td align="left" colspan="1" rowspan="1">Hypermethylation</td>
<td align="left" colspan="1" rowspan="1">Promote HOXA11-AS expression to induce EMT</td>
<td align="left" colspan="1" rowspan="1">[<a href="#CR50" class="usa-link" aria-describedby="CR50">50</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CRTAC1</td>
<td align="left" colspan="1" rowspan="1">Hypermethylation</td>
<td align="left" colspan="1" rowspan="1">Induces Ca2 + -dependent Akt1 degradation and apoptosis</td>
<td align="left" colspan="1" rowspan="1">[<a href="#CR53" class="usa-link" aria-describedby="CR53">53</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">IGFBP-3</td>
<td align="left" colspan="1" rowspan="1">Hypermethylation</td>
<td align="left" colspan="1" rowspan="1">Activate the PI3K/AKT pathway</td>
<td align="left" colspan="1" rowspan="1">[<a href="#CR54" class="usa-link" aria-describedby="CR54">54</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">FOXF1</td>
<td align="left" colspan="1" rowspan="1">Hypomethylation</td>
<td align="left" colspan="1" rowspan="1">Inhibit the apoptosis</td>
<td align="left" colspan="1" rowspan="1">[<a href="#CR143" class="usa-link" aria-describedby="CR143">143</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">MDR1</td>
<td align="left" colspan="1" rowspan="1">Hypomethylation</td>
<td align="left" colspan="1" rowspan="1">Enhance the expression of a P-gp</td>
<td align="left" colspan="1" rowspan="1">[<a href="#CR144" class="usa-link" aria-describedby="CR144">144</a>]</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section><p id="Par19">It enumerates multiple DNA methylation-regulated target genes associated with cisplatin resistance in lung cancer, along with their regulatory mechanisms. Notably, genes including NNT, HOXA11, and CRTAC1exhibit significant hypermethylation in cisplatin-resistant cells, resulting in their transcriptional silencing. This downregulation consequently impairs critical cellular processes such as apoptosis, and transporter protein expression, ultimately enhancing tumor cell chemoresistance. Conversely, other genes (e.g., FOXF1 and MDR1) demonstrate hypomethylation-mediated overexpression, which similarly contributes to drug resistance.</p>
<p id="Par20">Cisplatin resistance is mainly attributed to the hypermethylation of gene promoters. Methyltransferase inhibitors can reverse this hypermethylation, restoring cisplatin sensitivity. For instance, decitabine (DAC) and 5-aza-2’-deoxycytidine (5-AzadC) are methyltransferase inhibitors capable of reversing drug resistance. Low doses of 5-aza-2’-deoxycytidine and trichostatin A (TSA) can reduce DNA methylation levels and restore gene expression, thereby reversing resistance in A549/DDP cells [<a href="#CR46" class="usa-link" aria-describedby="CR46">46</a>]. Another methyltransferase inhibitor, decitabine (DAC), has been proved to reverse cisplatin resistance through demethylation in bladder cancer cells [<a href="#CR45" class="usa-link" aria-describedby="CR45">45</a>]. Moreover, the combination of methyltransferase inhibitors and cisplatin has shown a synergistic effect. For example, in cisplatin-resistant lung cancer cells, the DNA methyltransferase inhibitors azacytidine (AZA) and cisplatin together increased apoptosis by regulating levels of the metastasis inhibitor KiSS-1 [<a href="#CR51" class="usa-link" aria-describedby="CR51">51</a>]. Similarly, CRISPR/dCas9-based DNA methylation editing methods have demonstrated high efficiency and specificity in altering DNA methylation levels [<a href="#CR52" class="usa-link" aria-describedby="CR52">52</a>].</p>
<p id="Par21">DNA methylation abnormalities in certain genes can serve as clinical biomarkers for predicting cisplatin efficacy in lung cancer and may even represent potential therapeutic targets after drug resistance develops. Analysis of the Gene Expression Omnibus (GEO) database in NSCLC patients revealed that Cartilage Acidic Protein 1 (CRTAC1), which is highly expressed in normal lung tissues, undergoes promoter hypermethylation leading to its downregulation in tumors. Functional studies demonstrated that CRTAC1 overexpression enhances cisplatin sensitivity by inducing Ca2⁺-dependent Akt1 degradation and promoting apoptosis [<a href="#CR53" class="usa-link" aria-describedby="CR53">53</a>]. Clinical data further supported that patients with high CRTAC1 expression exhibited significantly prolonged overall survival (OS) following cisplatin treatment, suggesting CRTAC1 as a promising predictive biomarker for cisplatin response. Additionally, hypermethylation of tumor suppressor genes plays a crucial role in cisplatin resistance. For instance, in NSCLC specimens, unmethylated IGFBP-3 promoter status was associated with prolonged disease-free survival (DFS) in stage I patients, indicating that IGFBP-3 methylation status may serve as a clinical biomarker for cisplatin efficacy [<a href="#CR54" class="usa-link" aria-describedby="CR54">54</a>]. Similarly, CDH13 promoter hypermethylation is frequently observed in NSCLC tissues, and demethylation-induced restoration of CDH13 expression reverses cisplatin resistance, highlighting its potential as both a predictive marker and a therapeutic target [<a href="#CR55" class="usa-link" aria-describedby="CR55">55</a>].</p>
<p id="Par22">In summary, DNA hypermethylation is closely associated with cisplatin resistance in lung cancer. Inhibiting DNA methylation may reverse this resistance, potentially offering a promising treatment strategy for cisplatin-resistant lung cancer.</p></section><section id="Sec7"><h3 class="pmc_sec_title">Noncoding RNA</h3>
<p id="Par23">Noncoding RNA refers to RNA molecules that do not have the ability to encode proteins, including microRNA, long noncoding RNA, and circular RNA. These noncoding RNAs play crucial roles in various biological processes such as gene expression regulation, cell differentiation and development, and tumor occurrence and progression.</p>
<section id="Sec8"><h4 class="pmc_sec_title">MicroRNA</h4>
<p id="Par24">MiRNAs are single-stranded noncoding RNA molecules about 19–25 nucleotides long that regulate target genes by binding to their 3'untranslated region, inhibiting translation or promoting transcript degradation [<a href="#CR56" class="usa-link" aria-describedby="CR56">56</a>]. The role of miRNAs in the response of tumor cells to cisplatin and the development of cancer is becoming increasingly clear. Research has found that the expression of miRNAs in drug-resistant cancer cells differs significantly from that in drug-sensitive cells [<a href="#CR57" class="usa-link" aria-describedby="CR57">57</a>]. Aberrant expression of miRNAs has been associated with cisplatin sensitivity in lung cancer (Table <a href="#Tab2" class="usa-link">2</a>).
</p>
<section class="tw xbox font-sm" id="Tab2"><h5 class="obj_head">Table 2.</h5>
<div class="caption p"><p>Dysregulated noncoding RNAs relevant to cisplatin sensitivity in lung cancer</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">Epigenetic category</th>
<th align="left" colspan="1" rowspan="1">Molecule</th>
<th align="left" colspan="1" rowspan="1">Expression</th>
<th align="left" colspan="1" rowspan="1">Target/Pathway</th>
<th align="left" colspan="1" rowspan="1">Mechanisms of resistance</th>
<th align="left" colspan="1" rowspan="1">References</th>
</tr></thead>
<tbody>
<tr>
<td align="left" rowspan="5" colspan="1">MiRNA</td>
<td align="left" colspan="1" rowspan="1">MiR-155</td>
<td align="left" colspan="1" rowspan="1">↑</td>
<td align="left" colspan="1" rowspan="1">TP53</td>
<td align="left" colspan="1" rowspan="1">Inhibits apoptosis</td>
<td align="left" colspan="1" rowspan="1">[<a href="#CR60" class="usa-link" aria-describedby="CR60">60</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">MiR-488</td>
<td align="left" colspan="1" rowspan="1">↑</td>
<td align="left" colspan="1" rowspan="1">eIF3a</td>
<td align="left" colspan="1" rowspan="1">Activation of NER</td>
<td align="left" colspan="1" rowspan="1">[<a href="#CR61" class="usa-link" aria-describedby="CR61">61</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">MiR-182-5p</td>
<td align="left" colspan="1" rowspan="1">↓</td>
<td align="left" colspan="1" rowspan="1">GLI2/Hedgehog</td>
<td align="left" colspan="1" rowspan="1">Activate the survival signaling</td>
<td align="left" colspan="1" rowspan="1">[<a href="#CR62" class="usa-link" aria-describedby="CR62">62</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">MiR-27b</td>
<td align="left" colspan="1" rowspan="1">↓</td>
<td align="left" colspan="1" rowspan="1">Snail/EMT</td>
<td align="left" colspan="1" rowspan="1">Inhibition of EMT enhances sensitivity</td>
<td align="left" colspan="1" rowspan="1">[<a href="#CR65" class="usa-link" aria-describedby="CR65">65</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">MiR-204</td>
<td align="left" colspan="1" rowspan="1">↓</td>
<td align="left" colspan="1" rowspan="1">CAV1/AKT/Bad</td>
<td align="left" colspan="1" rowspan="1">Restore apoptotic signaling</td>
<td align="left" colspan="1" rowspan="1">[<a href="#CR67" class="usa-link" aria-describedby="CR67">67</a>]</td>
</tr>
<tr>
<td align="left" rowspan="5" colspan="1">LncRNA</td>
<td align="left" colspan="1" rowspan="1">UCA1</td>
<td align="left" colspan="1" rowspan="1">↑</td>
<td align="left" colspan="1" rowspan="1">PCNA/ERCC1</td>
<td align="left" colspan="1" rowspan="1">Enhances DNA repair</td>
<td align="left" colspan="1" rowspan="1">[<a href="#CR72" class="usa-link" aria-describedby="CR72">72</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">HOXA-AS3</td>
<td align="left" colspan="1" rowspan="1">↑</td>
<td align="left" colspan="1" rowspan="1">HOXA3</td>
<td align="left" colspan="1" rowspan="1">Mediates EMT to promote drug resistance</td>
<td align="left" colspan="1" rowspan="1">[<a href="#CR76" class="usa-link" aria-describedby="CR76">76</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">MALAT1</td>
<td align="left" colspan="1" rowspan="1">↑</td>
<td align="left" colspan="1" rowspan="1">STAT3</td>
<td align="left" colspan="1" rowspan="1">Increases MRP1/MDR1 expression</td>
<td align="left" colspan="1" rowspan="1">[<a href="#CR81" class="usa-link" aria-describedby="CR81">81</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Linc00665</td>
<td align="left" colspan="1" rowspan="1">↑</td>
<td align="left" colspan="1" rowspan="1">CDKN1C/EZH2</td>
<td align="left" colspan="1" rowspan="1">Cell cycle dysregulation</td>
<td align="left" colspan="1" rowspan="1">[<a href="#CR119" class="usa-link" aria-describedby="CR119">119</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">HOXA11-AS</td>
<td align="left" colspan="1" rowspan="1">↑</td>
<td align="left" colspan="1" rowspan="1">miR-454-3p/Stat3</td>
<td align="left" colspan="1" rowspan="1">Anti-apoptotic gene expression is upregulated</td>
<td align="left" colspan="1" rowspan="1">[<a href="#CR104" class="usa-link" aria-describedby="CR104">104</a>]</td>
</tr>
<tr>
<td align="left" rowspan="5" colspan="1">CircRNA</td>
<td align="left" colspan="1" rowspan="1">CircPVT1</td>
<td align="left" colspan="1" rowspan="1">↑</td>
<td align="left" colspan="1" rowspan="1">miR-145-5p/ABCC1</td>
<td align="left" colspan="1" rowspan="1">Activates transporter efflux</td>
<td align="left" colspan="1" rowspan="1">[<a href="#CR93" class="usa-link" aria-describedby="CR93">93</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Hsa_circ_0001946</td>
<td align="left" colspan="1" rowspan="1">↓</td>
<td align="left" colspan="1" rowspan="1">NER</td>
<td align="left" colspan="1" rowspan="1">Enhances DNA damage repair</td>
<td align="left" colspan="1" rowspan="1">[<a href="#CR95" class="usa-link" aria-describedby="CR95">95</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CircsSMARCA5</td>
<td align="left" colspan="1" rowspan="1">↓</td>
<td align="left" colspan="1" rowspan="1">miR-670-5p/RBM24</td>
<td align="left" colspan="1" rowspan="1">Inhibits tumor progression</td>
<td align="left" colspan="1" rowspan="1">[<a href="#CR96" class="usa-link" aria-describedby="CR96">96</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Circ_PIP5K1A</td>
<td align="left" colspan="1" rowspan="1">↑</td>
<td align="left" colspan="1" rowspan="1">miR-101/ABCC1</td>
<td align="left" colspan="1" rowspan="1">Dual drug-resistant pump control</td>
<td align="left" colspan="1" rowspan="1">[<a href="#CR99" class="usa-link" aria-describedby="CR99">99</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Circ_CPA4</td>
<td align="left" colspan="1" rowspan="1">↑</td>
<td align="left" colspan="1" rowspan="1">let-7/PD-L1</td>
<td align="left" colspan="1" rowspan="1">Immune evasion</td>
<td align="left" colspan="1" rowspan="1">[<a href="#CR102" class="usa-link" aria-describedby="CR102">102</a>]</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section><p id="Par25">This table summarizes the noncoding RNAs that are currently strongly associated with cisplatin sensitivity in lung cancer, detailing their expression alterations, target molecules, and functional mechanisms.</p>
<p id="Par26">Regulatory effects of miRNAs: The expression of MiR-155 and MiR-488 is upregulated, acting on TP53 and eIF3a, respectively, inhibiting apoptosis and activating the NER pathway to enhance drug resistance. Expression of MiR-182-5p, MiR-27b, and MiR-204 is downregulated and is involved in drug resistance regulation by activating survival signaling, affecting EMT, or restoring apoptosis signaling.</p>
<p id="Par27">Mediation mechanisms of LncRNAs: UCA1, HOXA-AS3, MALAT1, Linc00665, and HOXA11-AS are all upregulated, and they target different molecules or pathways to promote drug resistance by enhancing DNA repair, mediating EMT, activating signaling pathways, leading to cell cycle dysregulation, and upregulating anti-apoptotic genes.</p>
<p id="Par28">CircRNA involvement pathways: Upregulation of the expression of CircPVT1, Circ_PIP5K1A, and Circ_CPA4, which enhance drug resistance by activating transporter efflux, modulating resistance pump function, and mediating immune escape, respectively. Hsa_circ_0001946, CircsSMARCA5 expression is downregulated and participates in the drug resistance process by affecting DNA damage repair and inhibiting tumor progression. In summary, the above epigenetic molecules are involved in drug resistance through various pathways such as regulating apoptosis, DNA repair, EMT, drug efflux, and immune escape.</p>
<p id="Par29">For example, the oncogene miR-155 is upregulated in multiple human cancers and further increased in treatment-resistant tumors [<a href="#CR58" class="usa-link" aria-describedby="CR58">58</a>]. And, miR-155 has been shown to induce resistance to various chemotherapeutic agents, and its downregulation can resensitize tumors to chemotherapy. This process is mainly mediated through the miR-155/TP53 feedback loop. A combination of high miR-155 expression and low TP53 expression is significantly associated with shorter survival in lung cancer patients [<a href="#CR59" class="usa-link" aria-describedby="CR59">59</a>]. TP53, also known as p53, is a tumor suppressor gene located on human chromosome 17p13 [<a href="#CR60" class="usa-link" aria-describedby="CR60">60</a>]. In addition, miRNA-488 was found to be more expressed in A549/DDP-resistant cells and is associated with cisplatin resistance in two other NSCLC cells, H1299 and SK-MES-1 [<a href="#CR61" class="usa-link" aria-describedby="CR61">61</a>]. Conversely, some miRNAs are downregulated in cisplatin-resistant lung cancer cells. For instance, miR-182-5p is downregulated in cisplatin-resistant lung adenocarcinoma cells and modulates cisplatin resistance by directly targeting GLI2 in the hedgehog signaling pathway (HHSP) [<a href="#CR62" class="usa-link" aria-describedby="CR62">62</a>]. GLI2 is a transcriptional regulator of the hedgehog pathway, which is commonly reactivated in cancer [<a href="#CR63" class="usa-link" aria-describedby="CR63">63</a>]. Human bone marrow mesenchymal stem cell-derived exosome (BMSC-Exo) miR-193a can inhibit the progression of non-small cell lung cancer and promote the expression of miR-193a by downregulating its target gene LRRC1, thereby reducing cisplatin resistance in NSCLC cells [<a href="#CR64" class="usa-link" aria-describedby="CR64">64</a>].</p>
<p id="Par30">MiRNAs contribute to cisplatin resistance in lung cancer by targeting specific genes and proteins. Compared to NSCLC patient samples, miR-27b is expressed at lower levels in adjacent normal tissue controls. Snail, as a target protein of miR-27b, is inhibited when miR-27b is highly expressed, and miR-27b increases the sensitivity of NSCLC cells to cisplatin and promotes epithelial–mesenchymal transition in lung cancer by targeting Snail [<a href="#CR65" class="usa-link" aria-describedby="CR65">65</a>]. miRNAs are also involved in multiple signaling pathways related to cisplatin resistance in lung cancer. For example, miR-29c negatively regulates the PI3K/Akt pathway to inhibit cisplatin resistance in NSCLC cells, while miR-204 reduces cisplatin resistance in NSCLC by inhibiting the caveolin-1/AKT/Bad pathway [<a href="#CR66" class="usa-link" aria-describedby="CR66">66</a>, <a href="#CR67" class="usa-link" aria-describedby="CR67">67</a>]. Moreover, miRNAs can interact with each other and synergize with lncRNAs and circRNAs to influence chemosensitivity. For instance, Linc00173 acts as a competitive endogenous RNA (ceRNA) by “sponging” miRNA-218, thereby regulating the expression of Etk (Epithelial tyrosine kinase) and contributing to chemotherapy resistance in small cell lung cancer [<a href="#CR68" class="usa-link" aria-describedby="CR68">68</a>].</p></section><section id="Sec9"><h4 class="pmc_sec_title">Long noncoding RNA</h4>
<p id="Par31">Long noncoding RNAs (lncRNAs) are a class of non-protein-coding transcripts longer than 200 nucleotides [<a href="#CR69" class="usa-link" aria-describedby="CR69">69</a>]. LncRNAs can influence the sensitivity of lung cancer cells to cisplatin through various mechanisms, including modulating the expression of key genes and interacting with miRNAs [<a href="#CR70" class="usa-link" aria-describedby="CR70">70</a>].</p>
<p id="Par32">Aberrant expression of lncRNAs plays a significant role in tumorigenesis, development, and metastasis [<a href="#CR71" class="usa-link" aria-describedby="CR71">71</a>]. For instance, overexpression of lncRNA UCA1 has been shown to increase the proliferation and migration abilities of lung adenocarcinoma cells, enhance cisplatin resistance, and is more highly expressed in A549/DDP cells and lung adenocarcinoma tissues. This overexpression may be linked to increased levels of proliferating cell nuclear antigen (PCNA) and excision repair cross-complementation group 1 (ERCC1) [<a href="#CR72" class="usa-link" aria-describedby="CR72">72</a>]. Similarly, lncRNA UCA1 is upregulated in the tissues and cell lines of cisplatin-resistant ovarian cancer patients, including serum exosomes, and is involved in cisplatin resistance through the miR-143/FOSL2 pathway regulation [<a href="#CR73" class="usa-link" aria-describedby="CR73">73</a>]. Given its role in cancer progression and cisplatin resistance, UCA1 may serve as a potential diagnostic marker and therapeutic target. HOXA-AS3 is another lncRNA that is overexpressed in various human cancers, including lung cancer [<a href="#CR74" class="usa-link" aria-describedby="CR74">74</a>]. It is also significantly upregulated in lung cancer tissues and cells, and promotes cancer cell proliferation [<a href="#CR75" class="usa-link" aria-describedby="CR75">75</a>]. Recent findings suggest a potential link between HOXA-AS3 overexpression and cisplatin resistance. This overexpression enhances cisplatin resistance and induces EMT by downregulating HOXA3 expression [<a href="#CR76" class="usa-link" aria-describedby="CR76">76</a>]. LncRNAs can indirectly regulate ABC transporter gene expression through “sponge” miRNAs, or directly affect their chromatin status and promoter activity, thereby enhancing multidrug resistance as a whole [<a href="#CR77" class="usa-link" aria-describedby="CR77">77</a>]. LINC00707 has previously been reported to be an oncogene able to promote lung adenocarcinoma cell proliferation and metastasis. However, silencing LINC00707 can enhance cisplatin sensitivity in cisplatin-resistant NSCLC cells by inhibiting MRP1 and P-gp through spongy miR-145 [<a href="#CR78" class="usa-link" aria-describedby="CR78">78</a>].</p>
<p id="Par33">MALAT1, also known as NEAT2, is an extensively studied lncRNA in cancer [<a href="#CR79" class="usa-link" aria-describedby="CR79">79</a>]. First identified in NSCLC patients, MALAT1 is upregulated in relation to cell proliferation, invasion, metastasis, evasion of apoptosis, and DNA repair defects, indicating its role as an oncogene [<a href="#CR80" class="usa-link" aria-describedby="CR80">80</a>, <a href="#CR83" class="usa-link" aria-describedby="CR83">83</a>]. MALAT1 is closely linked to the development of drug resistance and has been shown to be upregulated in A549/DDP-resistant cell lines, reducing cisplatin sensitivity both in vitro and in vivo. This is likely due to the activation of STAT3, which upregulates MRP1 and MDR1 [<a href="#CR81" class="usa-link" aria-describedby="CR81">81</a>]. Additionally, MALAT1 forms a feedback loop with miR-101 and SOX9 to modulate cisplatin resistance through the Wnt signaling pathway [<a href="#CR82" class="usa-link" aria-describedby="CR82">82</a>]. Beyond cisplatin, MALAT1 has also been implicated in resistance to other chemotherapy drugs, such as gemcitabine, further enhancing resistance in NSCLC cells [<a href="#CR84" class="usa-link" aria-describedby="CR84">84</a>, <a href="#CR85" class="usa-link" aria-describedby="CR85">85</a>]. MALAT1 could serve as a comprehensive target for cisplatin-resistant therapy in lung cancer. lncRNAs are key factors regulating cisplatin sensitivity in lung cancer (Table <a href="#Tab2" class="usa-link">2</a>).</p></section><section id="Sec10"><h4 class="pmc_sec_title">Circular RNA</h4>
<p id="Par34">Circular RNAs (circRNAs) are covalently closed molecules that interact with mRNA and act as molecular sponges to regulate gene expression [<a href="#CR86" class="usa-link" aria-describedby="CR86">86</a>]. These RNAs have been found to be differentially expressed in tumors and normal tissues, including lung cancer, suggesting they may contribute to tumor development [<a href="#CR87" class="usa-link" aria-describedby="CR87">87</a>, <a href="#CR88" class="usa-link" aria-describedby="CR88">88</a>]. Recent studies have shown that circRNAs are closely related to cisplatin resistance and may serve as novel therapeutic targets [<a href="#CR89" class="usa-link" aria-describedby="CR89">89</a>–<a href="#CR91" class="usa-link" aria-describedby="CR91">91</a>] (Table <a href="#Tab2" class="usa-link">2</a>).</p>
<p id="Par35">Some circRNAs are aberrantly expressed in resistant tissues or cell lines in lung cancer. For example, circPVT1 is highly expressed in lung adenocarcinoma and upregulated in cisplatin- and pemetrexed-resistant tissues and cell lines. Knocking down circPVT1 expression can resensitize resistant cells to these drugs. CircPVT1 acts as a competitive endogenous RNA (ceRNA) for miR-145-5p, which targets ABCC1, thus contributing to cisplatin resistance by regulating the miR-145-5p/ABCC1 axis [<a href="#CR92" class="usa-link" aria-describedby="CR92">92</a>]. CircPVT1 is also clinically significant in NSCLC patients treated with cisplatin and gemcitabine. The therapeutic effect can be assessed by detecting circRNA expression in serum, as chemoresistant patients have reduced circPVT1 expression post-treatment compared to chemosensitive patients [<a href="#CR93" class="usa-link" aria-describedby="CR93">93</a>]. MiR-545-3p can inhibit the proliferation and migration of NSCLC cells and promote cisplatin-induced apoptosis. Circ_0072083 enhances the cisplatin inhibitory effect in NSCLC cells through the miR-545-3p/CBLL1 axis [<a href="#CR94" class="usa-link" aria-describedby="CR94">94</a>]. Some downregulated circRNAs are also involved in cisplatin resistance. For instance, has-circ-0001946 downregulation promotes NSCLC cell proliferation, migration, and invasion, affecting cisplatin sensitivity by modulating the NER signaling pathway [<a href="#CR95" class="usa-link" aria-describedby="CR95">95</a>]. CircsSMARCA5, a tumor suppressor gene, is expressed at low levels in NSCLC tissues and cells. Overexpression of circsSMARCA5 inhibits cell proliferation and enhances sensitivity to cisplatin and gemcitabine [<a href="#CR96" class="usa-link" aria-describedby="CR96">96</a>] [<a href="#CR97" class="usa-link" aria-describedby="CR97">97</a>].</p>
<p id="Par36">Additionally, dysregulated circRNAs contribute to cisplatin resistance through multiple pathways. ABC transporters, such as P-GP (MDR1) and MRP1, are associated with cisplatin resistance. Circ-0076305 is upregulated in drug-resistant NSCLC, leading to increased expression of these transporters [<a href="#CR98" class="usa-link" aria-describedby="CR98">98</a>]. Exosomes circ_PIP5K1A are overexpressed in NSCLC tissues and cells. Their knockout inhibits lung cancer progression and increases cisplatin sensitivity by modulating the miR-101/ABCC1 axis [<a href="#CR99" class="usa-link" aria-describedby="CR99">99</a>]. ABCC1, a member of the ATP-binding cassette subfamily C, reduces drug accumulation in cancer cells, contributing to resistance [<a href="#CR100" class="usa-link" aria-describedby="CR100">100</a>]. Exosomes are involved in cancer development and can promote tumor drug resistance [<a href="#CR101" class="usa-link" aria-describedby="CR101">101</a>]. Circ_CPA4 regulates Programmed death-ligand 1 (PD-L1) via the let-7 miRNA, promoting proliferation, invasion, EMT, and cisplatin resistance in lung cancer cells. This is due to PD-L1-containing exosomes increasing mRNA levels in stem cells and inactivating CD8 + T cells, leading to immune escape [<a href="#CR102" class="usa-link" aria-describedby="CR102">102</a>].</p>
<p id="Par37">Although numerous studies have elucidated the regulatory roles of noncoding RNAs in cisplatin resistance in lung cancer, conflicting findings regarding their specific functions persist, reflecting the complexity and inconsistency in current mechanistic interpretations. For instance, miR-488 has been reported by some studies to promote cisplatin resistance in lung cancer by targeting eIF3a and upregulating the NER pathway, thereby enhancing tumor cell DNA damage repair capacity and diminishing cisplatin efficacy. However, in other cancer types such as gastric cancer (GC), miR-488 may function as a tumor suppressor, suggesting its role is highly context-dependent and potentially influenced by tissue-specific regulatory networks [<a href="#CR103" class="usa-link" aria-describedby="CR103">103</a>]. Similarly, the lncRNA HOXA11-AS was found to drive cisplatin resistance by modulating the miR-454-3p/STAT3 signaling axis. Yet, other studies indicate that HOXA11-AS forms a bidirectional regulatory loop with the HOXA11 gene, where its overexpression suppresses HOXA11 and promotes resistance, while its inhibition restores cisplatin sensitivity [<a href="#CR104" class="usa-link" aria-describedby="CR104">104</a>]. Such intricate interactions highlight that lncRNA-mediated regulation is not solely dependent on expression levels but also involves competitive endogenous RNA (ceRNA) mechanisms.</p>
<p id="Par38">Furthermore, circPVT1 exhibits a dual role in cisplatin resistance. On one hand, it acts as a miR-145-5p sponge, upregulating ABCC1 expression and conferring resistance to cisplatin and pemetrexed in lung adenocarcinoma. On the other hand, while circPVT1 expression decreases post-treatment, it remains elevated compared to chemotherapy-sensitive patients, suggesting temporal or patient-specific heterogeneity in its functional impact [<a href="#CR93" class="usa-link" aria-describedby="CR93">93</a>]. These discrepancies may stem from variations across tumor types, different subtypes within the same cancer, or temporal dynamics during the development of cisplatin resistance. To address these inconsistencies, we can: (1) conduct large-scale clinical sample analyses to delineate expression patterns of specific ncRNAs across various lung cancer subtypes and treatment stages; (2) identify functionally stable ncRNAs; and (3) employ epigenetic editing tools like CRISPR/dCas9 to validate their causal regulatory relationships.</p>
<p id="Par39">As we all know, noncoding RNAs play pivotal roles in mediating cisplatin resistance in lung cancer. These findings highlight the therapeutic potential of targeting specific noncoding RNAs to enhance cisplatin efficacy and overcome drug resistance. Furthermore, the dysregulated expression patterns of these noncoding RNAs in lung cancer tissues and cells may serve as promising biomarkers for predicting chemotherapy response and patient prognosis.</p></section></section><section id="Sec11"><h3 class="pmc_sec_title">Histone modification</h3>
<p id="Par40">Histone modification, a crucial mechanism of epigenetic regulation, controls gene expression by altering the chemical modifications of histone tails (e.g., acetylation, methylation, phosphorylation) and affecting the structure and function of chromatin [<a href="#CR33" class="usa-link" aria-describedby="CR33">33</a>]. Recent studies have highlighted the role of histone modifications in cisplatin resistance in NSCLC.</p>
<p id="Par41">Histone methylation can be regulated by histone methyltransferases (HMTs) and demethylases, primarily by the addition or removal of methyl groups from amino acids [<a href="#CR105" class="usa-link" aria-describedby="CR105">105</a>, <a href="#CR106" class="usa-link" aria-describedby="CR106">106</a>]. These enzymes are involved in the occurrence and development of cancer and may even affect the efficacy of chemotherapy drugs [<a href="#CR105" class="usa-link" aria-describedby="CR105">105</a>, <a href="#CR107" class="usa-link" aria-describedby="CR107">107</a>, <a href="#CR108" class="usa-link" aria-describedby="CR108">108</a>]. MJD1 (also known as lysine demethylase 3 A [KDM3A]), a subfamily of JmjC histone demethylases, has been found to be upregulated in various cancers, promoting tumor growth and metastasis [<a href="#CR108" class="usa-link" aria-describedby="CR108">108</a>]. JMJD1B is overexpressed in lung cancer tissues and cell lines, increasing cell proliferation and invasion by inhibiting the expression of p53. Overexpressed JARID1B can also promote tumor aggressiveness by activating the c-MET signaling pathway and is associated with resistance to cisplatin and doxorubicin, which can be reversed by inhibiting their expression. This suggests that JARID1B may promote chemoresistance in NSCLC cells [<a href="#CR109" class="usa-link" aria-describedby="CR109">109</a>].</p>
<p id="Par42">The zeste enhancer homolog 2 (EZH2) is a catalytic subunit of the multicomb inhibitory complex 2 (PRC2) that mediates the methylation of H3K27, resulting in transcriptional silencing of genes involved in cell differentiation [<a href="#CR110" class="usa-link" aria-describedby="CR110">110</a>]. Dysregulation or overexpression of EZH2 promotes oncogenic transformation by altering chromatin structure and increasing H3K27me3 levels [<a href="#CR111" class="usa-link" aria-describedby="CR111">111</a>]. EZH2, a histone methyltransferase with catalytic activity, is overexpressed in lung cancer cells, where it activates STAT3 signaling upon myristoylation, promoting accelerated proliferation of lung cancer cells [<a href="#CR112" class="usa-link" aria-describedby="CR112">112</a>]. However, knocking down EZH2 using specific inhibitors can inhibit lung cancer cell proliferation while enhancing chemosensitivity to cisplatin [<a href="#CR113" class="usa-link" aria-describedby="CR113">113</a>]. EZH2 also directly binds to regulatory promoters, modulating gene expression. For instance, the PUMA (p53 upregulating regulator of apoptosis) promoter is conjugated by EZH2, and its expression is induced when EZH2 is inhibited, leading to increased sensitivity of NSCLC to cisplatin [<a href="#CR114" class="usa-link" aria-describedby="CR114">114</a>]. EZH2 can serve as a potential biomarker for lung cancer diagnosis and prognosis, as its overexpression is associated with poor outcomes in NSCLC patients [<a href="#CR115" class="usa-link" aria-describedby="CR115">115</a>]. In addition, cfDNA epiomics analysis showed that H3K4me3 upregulation and promoter hypomethylation synergistically activate oncogenes (such as CAV2 and PRKCI) in lung cancer, which can be used for early detection (sensitivity 95.1%) [<a href="#CR116" class="usa-link" aria-describedby="CR116">116</a>]. Also found that H3K27me3 modification affects NER and HR leading to chemotherapy resistance, suggesting that it also plays a driving role in drug resistance [<a href="#CR117" class="usa-link" aria-describedby="CR117">117</a>]. For example, SLFN11, which plays a role in DNA damage repair, is silenced in multiple chemoresistance models, and its silencing is associated with increased deposition of H3K27me3 catalyzed by EZH2. And, the addition of EZH2 inhibitors has been shown to enhance the sensitivity of lung cancer to chemotherapy [<a href="#CR118" class="usa-link" aria-describedby="CR118">118</a>]. Additionally, LINC00665 can recruit EZH2 into the promoter of cyclin-dependent kinase inhibitor 1 C (CDKN1C), promoting H3K27 demethylation and transcriptional repression, thereby exerting its tumorigenic effects and reducing sensitivity to cisplatin [<a href="#CR119" class="usa-link" aria-describedby="CR119">119</a>].</p>
<p id="Par43">Histone acetylation is another vital epigenetic mechanism regulating gene expression, primarily mediated by histone acetyltransferases (HATs) and histone deacetylases (HDACs), which work in opposing directions [<a href="#CR120" class="usa-link" aria-describedby="CR120">120</a>]. Aberrant expression of HATs and HDACs has been implicated in tumor initiation and progression [<a href="#CR121" class="usa-link" aria-describedby="CR121">121</a>]. Gene expression affected by histone acetylation can influence the sensitivity of cancer cells to chemotherapeutic agents. For example, overexpression of the excision repair cross-complementation 1 (ERCC1) gene has been shown to promote cisplatin resistance. However, histone deacetylase inhibitors (HDACis) can resensitize NSCLC cells with high ERCC1 expression to cisplatin. This occurs because HDACis induce miR-149 expression through acetylation and activation of E2F1, while inhibition of miR-149 reverses the DNA damage and apoptosis of NSCLC cells with cisplatin-induced ERCC1 overexpression by HDACis. Additionally, E2F1 can directly target ERCC1 and inhibit its expression [<a href="#CR122" class="usa-link" aria-describedby="CR122">122</a>]. PD-L1 is an immunosuppressive factor, and increased expression of PD-L1 in cancer cells has been linked to acquired chemoresistance [<a href="#CR123" class="usa-link" aria-describedby="CR123">123</a>]. PD-L1 expression is significantly elevated in cisplatin-resistant tissues and cell lines in NSCLC. This increase is associated with enhanced histone H3 acetylation of the PD-L1 promoter by the COP1/c-Jun/HDAC3 axis [<a href="#CR124" class="usa-link" aria-describedby="CR124">124</a>].</p>
<p id="Par44">These findings highlight the potential of targeting histone modifications to overcome cisplatin resistance in NSCLC. Future research should focus on developing specific inhibitors and exploring combination therapies to enhance patient outcomes.</p></section><section id="Sec12"><h3 class="pmc_sec_title">M6A modification</h3>
<p id="Par45">N6-methyladenosine (m6A) methylation, one of the most common RNA modifications, occurs through the METTL3/METTL14 methyltransferase complex and influences RNA stability and translation efficiency [<a href="#CR125" class="usa-link" aria-describedby="CR125">125</a>]. This modification is implicated in the onset and progression of various human cancers [<a href="#CR126" class="usa-link" aria-describedby="CR126">126</a>]. For example, m6A is highly enriched in mitochondrial RNA-processing endonuclease (RMRP) and enhances its RNA stability. This is mediated by m6A RNA methylation, which promotes the proliferation and progression of NSCLC by modulating the TGFBR1/SMAD2/SMAD3 pathway [<a href="#CR127" class="usa-link" aria-describedby="CR127">127</a>].</p>
<p id="Par46">M6A methylation has a potential association with cisplatin resistance in lung cancer. Overexpression of miR-4443, a tissue-derived exosome of cisplatin-resistant NSCLC, promotes cisplatin resistance by inhibiting cisplatin-induced FSP1-mediated ferroptosis [<a href="#CR128" class="usa-link" aria-describedby="CR128">128</a>]. The mechanism involved is that miR-4443 regulates the expression of FSP1 in an m6A-dependent manner through its direct target gene METTL3. In NSCLC, the methyltransferase METTL3 is frequently upregulated, enhancing the stability and translational efficiency of multiple drug resistance-related mRNAs. Specifically, METTL3 overexpression in lung cancer tissues and cells mediates m6A methylation of YAP mRNA, which recruits YTHDF1/3 and eIF3b to the translation initiation complex to promote YAP protein synthesis. Concurrently, METTL3 stabilizes YAP mRNA through the MALAT1-miR-1914-3p-YAP axis [<a href="#CR129" class="usa-link" aria-describedby="CR129">129</a>]. These coordinated mechanisms lead to increased YAP expression and activity, ultimately driving NSCLC chemoresistance and metastasis.</p>
<p id="Par47">Demethylases (“Erasers”) also contribute to drug resistance. For example, in KRAS-mutant NSCLC, KRAS activation suppresses ALKBH5 demethylase activity through the ERK/JNK signaling pathway, leading to elevated m6A levels. This enhances the stability of DDB2 and XPC mRNAs, thereby promoting NER and driving cisplatin resistance. Additionally, m6A-modified RNAs recruit reader proteins (e.g., IGF2BP1), which stabilize target transcripts by interacting with RNA-binding proteins such as ELAVL1 [<a href="#CR130" class="usa-link" aria-describedby="CR130">130</a>]. Specifically, m6A-dependent stabilization of SNRPA mRNA facilitates exon 8 skipping in ERCC1 pre-mRNA, generating the ERCC1-E8 (+) splice variant. This isoform forms the ERCC1-XPF heterodimer, a critical mediator of DNA damage repair, ultimately conferring cisplatin resistance in lung adenocarcinoma [<a href="#CR131" class="usa-link" aria-describedby="CR131">131</a>].</p>
<p id="Par48">The association between m6A modification and cisplatin resistance is primarily mediated by methyltransferases, demethylases, and reader proteins. These regulators modulate m6A levels to enhance the stability and translational efficiency of drug resistance-related RNAs.</p></section></section><section id="Sec13"><h2 class="pmc_sec_title">Epigenetic modification and clinical practice</h2>
<p id="Par49">Emerging research has established the critical role of epigenetic modifications in cisplatin resistance, though clinical translation remains in its nascent stages. Aberrant DNA methylation patterns are closely associated with cisplatin resistance, making DNA methylation modulation a promising therapeutic strategy. DNA methyltransferase inhibitors (DNMTis), such as decitabine (DAC)—currently approved for hematologic malignancies—demonstrate significant potential in NSCLC treatment and resistance reversal. In vitro studies indicate that low-dose 5-aza-2'-deoxycytidine combined with trichostatin A (TSA) can restore cisplatin sensitivity in A549/DDP cells. Furthermore, synergistic effects have been observed when DNMTis (e.g., azacitidine, AZA) are co-administered with cisplatin, significantly enhancing apoptosis in resistant NSCLC cells. While DNMTis for cisplatin resistance remain in preclinical investigation, their clinical applications in NSCLC are being actively explored, including CC-486 (oral azacitidine) combined with HDAC inhibitors (e.g., entinostat) in advanced NSCLC, though this regimen is associated with adverse effects such as injection-site reactions, gastrointestinal disturbances, and hyperglycemia [<a href="#CR132" class="usa-link" aria-describedby="CR132">132</a>]. A randomized phase II trial (<a href="https://clinicaltrials.gov/ct2/show/NCT02250326" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT02250326</a>) comparing nab-paclitaxel ± CC-486 in advanced non-squamous NSCLC patients showed no survival benefit with the combination therapy (<em>P</em> &gt; 0.05) [<a href="#CR133" class="usa-link" aria-describedby="CR133">133</a>]. Ongoing clinical studies (e.g., ChiCTR2400089355) are evaluating ctDNA methylation profiling to dynamically monitor treatment response and detect resistance earlier than conventional serum biomarkers in advanced NSCLC.</p>
<p id="Par50">Alterations in histone chemical modifications contribute to cisplatin resistance, with histone-targeting epigenetic modulators demonstrating therapeutic promise. Aberrant expression of histone methyltransferases and demethylases is observed in lung cancer, exemplified by EZH2 overexpression. Pharmacological inhibition of EZH2 enhances cisplatin sensitivity by directly binding to gene promoters and modulating transcriptional regulation. Clinical evidence correlates EZH2 overexpression with poor prognosis in NSCLC patients. Specific inhibitors (GSK126, DZNep) improve the sensitivity of BRG1/EGFR-mutant NSCLC cells to topoisomerase II inhibitors like etoposide, establishing a preclinical foundation for EZH2-targeted therapies [<a href="#CR134" class="usa-link" aria-describedby="CR134">134</a>].</p>
<p id="Par51">Similarly, histone deacetylase inhibitors (HDACis) resensitize NSCLC cells to cisplatin through multigene regulation. For instance, Vorinostat (a small-molecule HDACi) potentiates carboplatin/paclitaxel efficacy by inducing γ-H2AX (a DNA damage marker) and increasing α-tubulin acetylation (linked to microtubule stabilization). A phase II trial (<a href="https://clinicaltrials.gov/ct2/show/NCT00481078" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT00481078</a>) showed improved response rates with vorinostat combination therapy (34% vs. 12%, <em>P</em> = 0.02) but also higher grade 4 thrombocytopenia (18% vs. 3%) and two fatal adverse events, with no survival benefit [<a href="#CR135" class="usa-link" aria-describedby="CR135">135</a>].</p>
<p id="Par52">Specific miRNAs (e.g., miR-29c, miR-204) augment cisplatin sensitivity by suppressing the PI3K/AKT and CAV1/AKT pathways. Although the MRX34 (miR-34a liposomal injection) phase I trial (<a href="https://clinicaltrials.gov/ct2/show/NCT01829971" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT01829971</a>) was terminated early due to immune toxicity, it validated the clinical feasibility of noncoding RNAs modulation. Developing safer delivery systems (e.g., exosomes, lipid nanoparticles) for resistance-related noncoding RNAs could advance targeted therapy in precision oncology.</p>
<p id="Par53">While these trials have demonstrated that some epigenetic inhibitors, either in combination with chemotherapy or used alone, may offer new therapeutic strategies for lung cancer treatment. However, it still faces many challenges in clinical translation. First, these drugs often have dose-related toxicities, such as bone marrow suppression, gastrointestinal discomfort, and liver impairment, limiting their clinical tolerability and the possibility of sustainable treatment. For example, myelosuppression, as the main dose-limiting toxicity of DNMTis, was administered sequentially in combination with cisplatin in the treatment of urothelial carcinoma and GCSF was effective in preventing neutropenia, and the results showed that it was tolerable despite some additional myelosuppressive effects [<a href="#CR136" class="usa-link" aria-describedby="CR136">136</a>]. This provides a reference for lung cancer-related treatment. Moreover, there is currently a lack of effective biomarkers to screen patients sensitive to epigenetic treatment, which can lead to highly variable clinical trial results and unpredictable treatment response. In addition, epigenetic high plasticity is affected by tumor heterogeneity, reducing the efficacy of epigenetic inhibitors. For example, alterations in HDAC expression are more common in hematologic malignancies and solid tumors, and this heterogeneity of tumor cells may attenuate the therapeutic effect of HDACis, limiting its suitability in malignancies characterized by specific expression [<a href="#CR137" class="usa-link" aria-describedby="CR137">137</a>]. This has led to a deep reflection: whether it is possible to detect the relevant epigenetic genes of abnormal states for patient screening before using relevant drugs. When using inhibitors and related drugs, attention should be paid to dose adjustment and indication screening, and even targeted delivery in liposomal nanoparticles should be considered. In combination therapy, it is crucial to maintain time coherence and monitor the treatment effect dynamically. In addition, the development of highly sensitive biomarkers and the application of CRISPR epigenetic editing technology may be beneficial to enhance drug sensitivity.</p>
<p id="Par54">And it was found that different subtypes of NSCLC also showed differences in DNA methylation patterns, epigenetic regulation mechanisms, and chemotherapy resistance mechanisms. Significant differences in gene mutations (e.g., EGFR, KRAS vs. SOX2, TP63) and molecular background between LUAD and LUSC affect epigenetic regulatory pathways [<a href="#CR138" class="usa-link" aria-describedby="CR138">138</a>]. Moreover, large-scale methylation analysis showed that multiple DNA repair genes (such as MLH1, MSH2, and BRCA1) in NSCLC exhibited differential hypermethylation patterns in the promoter region in different isotypes [<a href="#CR139" class="usa-link" aria-describedby="CR139">139</a>]. Hypermethylation and silencing of common tumor suppressor genes in LUAD, such as RASSF1A, are closely related to increased drug resistance, while LUSC exhibits more prevalent chromatin remodeling abnormalities in the genome, suggesting that its epigenetic regulatory mechanism is different from that of LUAD [<a href="#CR46" class="usa-link" aria-describedby="CR46">46</a>]. Again, miRNA expression profiles differ significantly between the two isotypes. Classical studies have shown that miRNAs (e.g., miR-21, miR-205, etc.) are expressed differently in LUAD versus LUSC, reflecting the specificity of epigenetic regulation [<a href="#CR140" class="usa-link" aria-describedby="CR140">140</a>]. In addition, although some signaling pathways in lung cancer, especially NSCLC, share some mechanisms with other cancers, they may exhibit some unique details in epigenetic regulation in the specific context of lung cancer. For example, the PI3K/AKT signaling pathway, which is more central in NSCLC, is often abnormally activated, with an activation mutation rate of PIK3CA (encoding the PI3K catalytic subunit p110α) of about 2–5%, while the tumor suppressor gene PTEN (negatively regulated PI3K/AKT) is absent or apparently silenced in about 8% of NSCLC, resulting in continued activation of AKT [<a href="#CR141" class="usa-link" aria-describedby="CR141">141</a>]. This aberrant activation is closely related to drug resistance, and it is particularly involved in miRNA regulation imbalances in epigenetic regulation. On the one hand. miR-204 reduces cisplatin resistance in NSCLC by inhibiting the caveolin-1/AKT/Bad pathway miR‑204. On the other hand, upregulation of miR-25-3p negatively regulates the PI3K/AKT pathway by downregulating PTEN release, leading to enhanced AKT activity and promoting the formation of a more significant cisplatin-resistant phenotype in NSCLC cells in vitro and in vitro experiments [<a href="#CR142" class="usa-link" aria-describedby="CR142">142</a>]. These findings suggest that when studying the relationship between epigenetic regulation and cisplatin resistance, it is necessary to consider both the tumor heterogeneity of NSCLC subtypes and the complexity of signaling pathway regulation, which may more accurately identify drug resistance mechanisms and promote the development of precision treatment strategies.</p></section><section id="Sec14"><h2 class="pmc_sec_title">Conclusion</h2>
<p id="Par55">Extensive studies have demonstrated that epigenetic modifications, including histone modifications, DNA methylation, and noncoding RNA regulation, play a pivotal role in cisplatin resistance in lung cancer. These findings have accelerated the development of novel biomarkers. For instance, noncoding RNAs such as MALAT1, circPTK1, and miR-29c exhibit altered expression levels in body fluids, exosomes, or tumor tissues, demonstrating strong correlations with cisplatin response and patient prognosis. These molecules hold great potential as liquid biopsy biomarkers for real-time monitoring of therapeutic efficacy.</p>
<p id="Par56">Furthermore, epigenetic inhibitors, including DNA methyltransferase inhibitors (DNMTis, e.g., azacitidine [AzaC] and decitabine [AzadC]) and histone deacetylase inhibitors (HDACis, e.g., vorinostat), have shown promising results in both preclinical and clinical studies. These agents not only enhance cisplatin sensitivity but also exhibit synergistic effects when combined with chemotherapy or radiotherapy, offering new therapeutic strategies to overcome cisplatin resistance. However, their clinical efficacy, toxicity, and side effects remain significant challenges that cannot be overlooked.</p>
<p id="Par57">Emerging technologies are also opening new avenues for breakthroughs in this field. Recent advances in CRISPR-based epigenetic editing tools (e.g., CRISPR/dCas9-DNMT/TET and CRISPR/dCas13) enable precise modulation of gene promoter methylation or RNA targeting, demonstrating remarkable potential in reversing drug-resistant phenotypes. For example, the CRISPR/dCas9-TET1 system has been successfully employed to demethylate the NNT promoter, restoring its expression and resensitizing resistant cancer cells to cisplatin. These breakthroughs suggest that precision epigenetic editing may serve as a key platform for personalized epigenetic therapy in the future.</p>
<p id="Par58">Although the role of epigenetic mechanisms in cisplatin resistance has received widespread attention, the clinical translation of epigenetic therapy still faces significant challenges. First, epigenetic drugs lack high specificity, which may lead to off-target effects and systemic toxicity. Also, there is no uniform and reliable biomarker for screening beneficiary patients. In addition, the complex heterogeneity of solid tumors also makes epigenetic treatment effects variable. Therefore, future research should focus on the development of liquid biopsy markers to monitor the evolution of drug resistance, and the application prospects of precise epigenetic editing technologies such as CRISPR/dCas9 in lung cancer.</p></section><section id="ack1" class="ack"><h2 class="pmc_sec_title">Acknowledgements</h2>
<p>Not applicable.</p></section><section id="notes1"><h2 class="pmc_sec_title">Author contributions</h2>
<p>Xiaoyan Yu drafted this review and designed the figures; Luyu Jia, Qing Tang and Qichun Zhou completed the data collection and provided editorial assistance; and Genshu Wang and Sumei Wang obtain funding supports and modified the manuscript. All authors made substantial, direct, and intellectual contribution to the review. All authors read and approved the final manuscript.</p></section><section id="notes2"><h2 class="pmc_sec_title">Funding</h2>
<p>This study was supported by grants from the Natural Science Foundation of China (82274602, 82104960), the Natural Science Foundation of Guangdong Province (2021A1515220023, 2023B1212060063), the Guangzhou science and technology plan project (2024A03J0548, 2024A03J0051, 202206010039, 202201011131), the Research Fund of Guangdong Provincial Hospital of Chinese Medicine (YN2024GZRPY002, YN2024GZRPY078, YN2022MS14), the State Key Laboratory of Traditional Chinese Medicine Syndrome (QZ2023ZZ47), the Key project of State Key Laboratory of dampness syndrome of Chinese medicine jointly built by province and Ministry (SZ2021ZZ38), the Guangdong Provincial Key Laboratory of Chinese Medicine for Prevention and Treatment of Refractory Chronic Diseases (2023KT15521), the Scientific Research Project in Universities of Guangdong Provincial Department of Education (2024KTSCX111), and the Guangdong traditional Chinese medicine project (20231094, 20241135).</p></section><section id="notes3"><h2 class="pmc_sec_title">Data availability</h2>
<p>Not applicable.</p></section><section id="notes4"><h2 class="pmc_sec_title">Declarations</h2>
<section id="FPar1"><h3 class="pmc_sec_title">Ethics approval and consent to participate</h3>
<p id="Par59">Not applicable.</p></section><section id="FPar2"><h3 class="pmc_sec_title">Competing interests</h3>
<p id="Par60">The authors declare no competing interests.</p></section></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm"><div class="fn p" id="fn1">
<p><strong>Publisher's Note</strong></p>
<p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</div></div></section><section id="_ci93_" lang="en" class="contrib-info"><h2 class="pmc_sec_title">Contributor Information</h2>
<p>Genshu Wang, Email: wgsh168@163.com.</p>
<p>Sumei Wang, Email: wangsumei198708@163.com.</p></section><section id="Bib1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="Bib1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="CR1">
<span class="label">1.</span><cite>Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide from cancers in 36 countries worldwide. CA: Cancer journal for clinicians. 2024;74(3):229–63.</cite> [<a href="https://doi.org/10.3322/caac.21834" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38572751/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Bray%20F,%20et%20al.%20Global%20cancer%20statistics%202022:%20GLOBOCAN%20estimates%20of%20incidence%20and%20mortality%20worldwide%20from%20cancers%20in%2036%20countries%20worldwide.%20CA:%20Cancer%20journal%20for%20clinicians.%202024;74(3):229%E2%80%9363." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR2">
<span class="label">2.</span><cite>Thai AA, et al. Lung cancer. Lancet. 2021;398(10299):535–54.
</cite> [<a href="https://doi.org/10.1016/S0140-6736(21)00312-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34273294/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Thai%20AA,%20et%20al.%20Lung%20cancer.%20Lancet.%202021;398(10299):535%E2%80%9354." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR3">
<span class="label">3.</span><cite>Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(1):39–51.
</cite> [<a href="https://doi.org/10.1016/j.jtho.2015.09.009" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26762738/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Goldstraw%20P,%20Chansky%20K,%20Crowley%20J,%20et%20al.%20The%20IASLC%20lung%20cancer%20staging%20project:%20proposals%20for%20revision%20of%20the%20TNM%20stage%20groupings%20in%20the%20forthcoming%20(eighth)%20edition%20of%20the%20TNM%20classification%20for%20lung%20cancer.%20J%20Thorac%20Oncol.%202016;11(1):39%E2%80%9351." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR4">
<span class="label">4.</span><cite>Horn L, Mansfield AS, Szczęsna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220–9.
</cite> [<a href="https://doi.org/10.1056/NEJMoa1809064" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30280641/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Horn%20L,%20Mansfield%20AS,%20Szcz%C4%99sna%20A,%20et%20al.%20First-line%20atezolizumab%20plus%20chemotherapy%20in%20extensive-stage%20small-cell%20lung%20cancer.%20N%20Engl%20J%20Med.%202018;379(23):2220%E2%80%939." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR5">
<span class="label">5.</span><cite>Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group. J Clin Oncol. 2008;26(21):3552–9.
</cite> [<a href="https://doi.org/10.1200/JCO.2007.13.9030" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18506026/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Pignon%20JP,%20Tribodet%20H,%20Scagliotti%20GV,%20et%20al.%20Lung%20adjuvant%20cisplatin%20evaluation:%20a%20pooled%20analysis%20by%20the%20LACE%20collaborative%20group.%20J%20Clin%20Oncol.%202008;26(21):3552%E2%80%939." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR6">
<span class="label">6.</span><cite>O’Grady S, Finn SP, Cuffe S, Richard DJ, O’Byrne KJ, Barr MP. The role of DNA repair pathways in cisplatin resistant lung cancer. Cancer Treat Rev. 2014;40(10):1161–70.
</cite> [<a href="https://doi.org/10.1016/j.ctrv.2014.10.003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25458603/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?O%E2%80%99Grady%20S,%20Finn%20SP,%20Cuffe%20S,%20Richard%20DJ,%20O%E2%80%99Byrne%20KJ,%20Barr%20MP.%20The%20role%20of%20DNA%20repair%20pathways%20in%20cisplatin%20resistant%20lung%20cancer.%20Cancer%20Treat%20Rev.%202014;40(10):1161%E2%80%9370." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR7">
<span class="label">7.</span><cite>Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003;22(47):7265–79.
</cite> [<a href="https://doi.org/10.1038/sj.onc.1206933" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/14576837/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Siddik%20ZH.%20Cisplatin:%20mode%20of%20cytotoxic%20action%20and%20molecular%20basis%20of%20resistance.%20Oncogene.%202003;22(47):7265%E2%80%9379." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR8">
<span class="label">8.</span><cite>Ghosh S. Cisplatin: the first metal based anticancer drug. Bioorg Chem. 2019;88: 102925.
</cite> [<a href="https://doi.org/10.1016/j.bioorg.2019.102925" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31003078/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ghosh%20S.%20Cisplatin:%20the%20first%20metal%20based%20anticancer%20drug.%20Bioorg%20Chem.%202019;88:%20102925." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR9">
<span class="label">9.</span><cite>Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007;7(8):573–84.
</cite> [<a href="https://doi.org/10.1038/nrc2167" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17625587/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kelland%20L.%20The%20resurgence%20of%20platinum-based%20cancer%20chemotherapy.%20Nat%20Rev%20Cancer.%202007;7(8):573%E2%80%9384." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR10">
<span class="label">10.</span><cite>Ferreira JA, Peixoto A, Neves M, et al. Mechanisms of cisplatin resistance and targeting of cancer stem cells: adding glycosylation to the equation. Drug Resist Updat. 2016;24:34–54.
</cite> [<a href="https://doi.org/10.1016/j.drup.2015.11.003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26830314/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ferreira%20JA,%20Peixoto%20A,%20Neves%20M,%20et%20al.%20Mechanisms%20of%20cisplatin%20resistance%20and%20targeting%20of%20cancer%20stem%20cells:%20adding%20glycosylation%20to%20the%20equation.%20Drug%20Resist%20Updat.%202016;24:34%E2%80%9354." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR11">
<span class="label">11.</span><cite>Li F, Zheng Z, Chen W, et al. Regulation of cisplatin resistance in bladder cancer by epigenetic mechanisms. Drug Resist Updat. 2023;68: 100938.
</cite> [<a href="https://doi.org/10.1016/j.drup.2023.100938" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36774746/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Li%20F,%20Zheng%20Z,%20Chen%20W,%20et%20al.%20Regulation%20of%20cisplatin%20resistance%20in%20bladder%20cancer%20by%20epigenetic%20mechanisms.%20Drug%20Resist%20Updat.%202023;68:%20100938." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR12">
<span class="label">12.</span><cite>Mondal P, Meeran SM. Emerging role of non-coding RNAs in resistance to platinum-based anti-cancer agents in lung cancer. Front Pharmacol. 2023;14:1105484.
</cite> [<a href="https://doi.org/10.3389/fphar.2023.1105484" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9909610/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36778005/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Mondal%20P,%20Meeran%20SM.%20Emerging%20role%20of%20non-coding%20RNAs%20in%20resistance%20to%20platinum-based%20anti-cancer%20agents%20in%20lung%20cancer.%20Front%20Pharmacol.%202023;14:1105484." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR13">
<span class="label">13.</span><cite>Loren P, Saavedra N, Saavedra K, et al. Contribution of microRNAs in chemoresistance to cisplatin in the top five deadliest cancer: an updated review. Front Pharmacol. 2022;13: 831099.
</cite> [<a href="https://doi.org/10.3389/fphar.2022.831099" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9015654/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35444536/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Loren%20P,%20Saavedra%20N,%20Saavedra%20K,%20et%20al.%20Contribution%20of%20microRNAs%20in%20chemoresistance%20to%20cisplatin%20in%20the%20top%20five%20deadliest%20cancer:%20an%20updated%20review.%20Front%20Pharmacol.%202022;13:%20831099." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR14">
<span class="label">14.</span><cite>Singh D, Assaraf YG, Gacche RN. Long non-coding RNA mediated drug resistance in breast cancer. Drug Resist Updat. 2022;63: 100851.
</cite> [<a href="https://doi.org/10.1016/j.drup.2022.100851" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35810716/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Singh%20D,%20Assaraf%20YG,%20Gacche%20RN.%20Long%20non-coding%20RNA%20mediated%20drug%20resistance%20in%20breast%20cancer.%20Drug%20Resist%20Updat.%202022;63:%20100851." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR15">
<span class="label">15.</span><cite>Hannon M. Metal-based anticancer drugs: From a past anchored in platinum chemistry to a post-genomic future of diverse chemistry and biology. Pure Appl Chem. 2007;79(12):2243–61.</cite> [<a href="https://scholar.google.com/scholar_lookup?Hannon%20M.%20Metal-based%20anticancer%20drugs:%20From%20a%20past%20anchored%20in%20platinum%20chemistry%20to%20a%20post-genomic%20future%20of%20diverse%20chemistry%20and%20biology.%20Pure%20Appl%20Chem.%202007;79(12):2243%E2%80%9361." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR16">
<span class="label">16.</span><cite>Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364–78.
</cite> [<a href="https://doi.org/10.1016/j.ejphar.2014.07.025" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4146684/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25058905/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Dasari%20S,%20Tchounwou%20PB.%20Cisplatin%20in%20cancer%20therapy:%20molecular%20mechanisms%20of%20action.%20Eur%20J%20Pharmacol.%202014;740:364%E2%80%9378." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR17">
<span class="label">17.</span><cite>Achkar IW, Abdulrahman N, Al-Sulaiti H, Joseph JM, Uddin S, Mraiche F. Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway. J Transl Med. 2018;16(1):96.
</cite> [<a href="https://doi.org/10.1186/s12967-018-1471-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5896132/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29642900/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Achkar%20IW,%20Abdulrahman%20N,%20Al-Sulaiti%20H,%20Joseph%20JM,%20Uddin%20S,%20Mraiche%20F.%20Cisplatin%20based%20therapy:%20the%20role%20of%20the%20mitogen%20activated%20protein%20kinase%20signaling%20pathway.%20J%20Transl%20Med.%202018;16(1):96." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR18">
<span class="label">18.</span><cite>Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev. 2007;33(1):9–23.
</cite> [<a href="https://doi.org/10.1016/j.ctrv.2006.09.006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC1855222/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17084534/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Rabik%20CA,%20Dolan%20ME.%20Molecular%20mechanisms%20of%20resistance%20and%20toxicity%20associated%20with%20platinating%20agents.%20Cancer%20Treat%20Rev.%202007;33(1):9%E2%80%9323." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR19">
<span class="label">19.</span><cite>Florea AM, Büsselberg D. Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers (Basel). 2011;3(1):1351–71.
</cite> [<a href="https://doi.org/10.3390/cancers3011351" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3756417/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24212665/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Florea%20AM,%20B%C3%BCsselberg%20D.%20Cisplatin%20as%20an%20anti-tumor%20drug:%20cellular%20mechanisms%20of%20activity,%20drug%20resistance%20and%20induced%20side%20effects.%20Cancers%20(Basel).%202011;3(1):1351%E2%80%9371." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR20">
<span class="label">20.</span><cite>Macerelli M, Ganzinelli M, Gouedard C, et al. Can the response to a platinum-based therapy be predicted by the DNA repair status in non-small cell lung cancer? Cancer Treat Rev. 2016;48:8–19.
</cite> [<a href="https://doi.org/10.1016/j.ctrv.2016.05.004" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27262017/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Macerelli%20M,%20Ganzinelli%20M,%20Gouedard%20C,%20et%20al.%20Can%20the%20response%20to%20a%20platinum-based%20therapy%20be%20predicted%20by%20the%20DNA%20repair%20status%20in%20non-small%20cell%20lung%20cancer?%20Cancer%20Treat%20Rev.%202016;48:8%E2%80%9319." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR21">
<span class="label">21.</span><cite>Duan M, Ulibarri J, Liu KJ, Mao P. Role of nucleotide excision repair in cisplatin resistance. Int J Mol Sci. 2020;21(23): 9248.
</cite> [<a href="https://doi.org/10.3390/ijms21239248" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7730652/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33291532/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Duan%20M,%20Ulibarri%20J,%20Liu%20KJ,%20Mao%20P.%20Role%20of%20nucleotide%20excision%20repair%20in%20cisplatin%20resistance.%20Int%20J%20Mol%20Sci.%202020;21(23):%209248." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR22">
<span class="label">22.</span><cite>Vaisman A, Varchenko M, Umar A, et al. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res. 1998;58(16):3579–85.
</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/9721864/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Vaisman%20A,%20Varchenko%20M,%20Umar%20A,%20et%20al.%20The%20role%20of%20hMLH1,%20hMSH3,%20and%20hMSH6%20defects%20in%20cisplatin%20and%20oxaliplatin%20resistance:%20correlation%20with%20replicative%20bypass%20of%20platinum-DNA%20adducts.%20Cancer%20Res.%201998;58(16):3579%E2%80%9385." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR23">
<span class="label">23.</span><cite>Selvakumaran M, Pisarcik DA, Bao R, Yeung AT, Hamilton TC. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res. 2003;63(6):1311–6.
</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/12649192/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Selvakumaran%20M,%20Pisarcik%20DA,%20Bao%20R,%20Yeung%20AT,%20Hamilton%20TC.%20Enhanced%20cisplatin%20cytotoxicity%20by%20disturbing%20the%20nucleotide%20excision%20repair%20pathway%20in%20ovarian%20cancer%20cell%20lines.%20Cancer%20Res.%202003;63(6):1311%E2%80%936." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR24">
<span class="label">24.</span><cite>Suzuki T, Sirimangkalakitti N, Baba A, et al. Characterization of the nucleotide excision repair pathway and evaluation of compounds for overcoming the cisplatin resistance of non-small cell lung cancer cell lines. Oncol Rep. 2022;47(4):70.
</cite> [<a href="https://doi.org/10.3892/or.2022.8281" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35147203/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Suzuki%20T,%20Sirimangkalakitti%20N,%20Baba%20A,%20et%20al.%20Characterization%20of%20the%20nucleotide%20excision%20repair%20pathway%20and%20evaluation%20of%20compounds%20for%20overcoming%20the%20cisplatin%20resistance%20of%20non-small%20cell%20lung%20cancer%20cell%20lines.%20Oncol%20Rep.%202022;47(4):70." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR25">
<span class="label">25.</span><cite>Fuertes MA, Alonso C, Pérez JM. Biochemical modulation of Cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance. Chem Rev. 2003;103(3):645–62.
</cite> [<a href="https://doi.org/10.1021/cr020010d" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12630848/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Fuertes%20MA,%20Alonso%20C,%20P%C3%A9rez%20JM.%20Biochemical%20modulation%20of%20Cisplatin%20mechanisms%20of%20action:%20enhancement%20of%20antitumor%20activity%20and%20circumvention%20of%20drug%20resistance.%20Chem%20Rev.%202003;103(3):645%E2%80%9362." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR26">
<span class="label">26.</span><cite>Ishida S, Lee J, Thiele DJ, Herskowitz I. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci U S A. 2002;99(22):14298–302.
</cite> [<a href="https://doi.org/10.1073/pnas.162491399" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC137878/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12370430/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ishida%20S,%20Lee%20J,%20Thiele%20DJ,%20Herskowitz%20I.%20Uptake%20of%20the%20anticancer%20drug%20cisplatin%20mediated%20by%20the%20copper%20transporter%20Ctr1%20in%20yeast%20and%20mammals.%20Proc%20Natl%20Acad%20Sci%20U%20S%20A.%202002;99(22):14298%E2%80%93302." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR27">
<span class="label">27.</span><cite>Bodiga S, Vemuri PK, Bodiga VL. Low Ctr1p, due to lack of Sco1p results in lowered cisplatin uptake and mediates insensitivity of rho0 yeast to cisplatin. J Inorg Biochem. 2018;187:14–24.
</cite> [<a href="https://doi.org/10.1016/j.jinorgbio.2018.07.003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30041154/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Bodiga%20S,%20Vemuri%20PK,%20Bodiga%20VL.%20Low%20Ctr1p,%20due%20to%20lack%20of%20Sco1p%20results%20in%20lowered%20cisplatin%20uptake%20and%20mediates%20insensitivity%20of%20rho0%20yeast%20to%20cisplatin.%20J%20Inorg%20Biochem.%202018;187:14%E2%80%9324." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR28">
<span class="label">28.</span><cite>Qu YQ, Song LL, Xu SW, et al. Pomiferin targets SERCA, mTOR, and P-gp to induce autophagic cell death in apoptosis-resistant cancer cells, and reverses the MDR phenotype in cisplatin-resistant tumors in vivo. Pharmacol Res. 2023;191: 106769.
</cite> [<a href="https://doi.org/10.1016/j.phrs.2023.106769" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37061145/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Qu%20YQ,%20Song%20LL,%20Xu%20SW,%20et%20al.%20Pomiferin%20targets%20SERCA,%20mTOR,%20and%20P-gp%20to%20induce%20autophagic%20cell%20death%20in%20apoptosis-resistant%20cancer%20cells,%20and%20reverses%20the%20MDR%20phenotype%20in%20cisplatin-resistant%20tumors%20in%20vivo.%20Pharmacol%20Res.%202023;191:%20106769." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR29">
<span class="label">29.</span><cite>Katano K, Kondo A, Safaei R, et al. Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. Cancer Res. 2002;62(22):6559–65.
</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/12438251/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Katano%20K,%20Kondo%20A,%20Safaei%20R,%20et%20al.%20Acquisition%20of%20resistance%20to%20cisplatin%20is%20accompanied%20by%20changes%20in%20the%20cellular%20pharmacology%20of%20copper.%20Cancer%20Res.%202002;62(22):6559%E2%80%9365." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR30">
<span class="label">30.</span><cite>Wu DW, Wu TC, Wu JY, et al. Phosphorylation of paxillin confers cisplatin resistance in non-small cell lung cancer via activating ERK-mediated Bcl-2 expression. Oncogene. 2014;33(35):4385–95.
</cite> [<a href="https://doi.org/10.1038/onc.2013.389" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24096476/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wu%20DW,%20Wu%20TC,%20Wu%20JY,%20et%20al.%20Phosphorylation%20of%20paxillin%20confers%20cisplatin%20resistance%20in%20non-small%20cell%20lung%20cancer%20via%20activating%20ERK-mediated%20Bcl-2%20expression.%20Oncogene.%202014;33(35):4385%E2%80%9395." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR31">
<span class="label">31.</span><cite>Perego P, Giarola M, Righetti SC, et al. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res. 1996;56(3):556–62.
</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/8564971/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Perego%20P,%20Giarola%20M,%20Righetti%20SC,%20et%20al.%20Association%20between%20cisplatin%20resistance%20and%20mutation%20of%20p53%20gene%20and%20reduced%20bax%20expression%20in%20ovarian%20carcinoma%20cell%20systems.%20Cancer%20Res.%201996;56(3):556%E2%80%9362." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR32">
<span class="label">32.</span><cite>Zhao J, Tan W, Zhang L, et al. FGFR3 phosphorylates EGFR to promote cisplatin-resistance in ovarian cancer. Biochem Pharmacol. 2021;190: 114536.
</cite> [<a href="https://doi.org/10.1016/j.bcp.2021.114536" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33794187/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhao%20J,%20Tan%20W,%20Zhang%20L,%20et%20al.%20FGFR3%20phosphorylates%20EGFR%20to%20promote%20cisplatin-resistance%20in%20ovarian%20cancer.%20Biochem%20Pharmacol.%202021;190:%20114536." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR33">
<span class="label">33.</span><cite>Zhang Y, Sun Z, Jia J, et al. Overview of Histone Modification. Adv Exp Med Biol. 2021;1283:1–16.
</cite> [<a href="https://doi.org/10.1007/978-981-15-8104-5_1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33155134/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhang%20Y,%20Sun%20Z,%20Jia%20J,%20et%20al.%20Overview%20of%20Histone%20Modification.%20Adv%20Exp%20Med%20Biol.%202021;1283:1%E2%80%9316." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR34">
<span class="label">34.</span><cite>Ansari J, Shackelford RE, El-Osta H. Epigenetics in non-small cell lung cancer: from basics to therapeutics. Transl Lung Cancer Res. 2016;5(2):155–71.
</cite> [<a href="https://doi.org/10.21037/tlcr.2016.02.02" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4858572/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27186511/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ansari%20J,%20Shackelford%20RE,%20El-Osta%20H.%20Epigenetics%20in%20non-small%20cell%20lung%20cancer:%20from%20basics%20to%20therapeutics.%20Transl%20Lung%20Cancer%20Res.%202016;5(2):155%E2%80%9371." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR35">
<span class="label">35.</span><cite>Mari-Alexandre J, Diaz-Lagares A, Villalba M, et al. Translating cancer epigenomics into the clinic: focus on lung cancer. Transl Res. 2017;189:76–92.
</cite> [<a href="https://doi.org/10.1016/j.trsl.2017.05.008" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28644958/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Mari-Alexandre%20J,%20Diaz-Lagares%20A,%20Villalba%20M,%20et%20al.%20Translating%20cancer%20epigenomics%20into%20the%20clinic:%20focus%20on%20lung%20cancer.%20Transl%20Res.%202017;189:76%E2%80%9392." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR36">
<span class="label">36.</span><cite>O’Byrne KJ, Barr MP, Gray SG. The role of epigenetics in resistance to Cisplatin chemotherapy in lung cancer. Cancers (Basel). 2011;3(1):1426–53.
</cite> [<a href="https://doi.org/10.3390/cancers3011426" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3756421/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24212667/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?O%E2%80%99Byrne%20KJ,%20Barr%20MP,%20Gray%20SG.%20The%20role%20of%20epigenetics%20in%20resistance%20to%20Cisplatin%20chemotherapy%20in%20lung%20cancer.%20Cancers%20(Basel).%202011;3(1):1426%E2%80%9353." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR37">
<span class="label">37.</span><cite>Moore LD, Le T, Fan G. DNA methylation and its basic function. Neuropsychopharmacology. 2013;38(1):23–38.
</cite> [<a href="https://doi.org/10.1038/npp.2012.112" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3521964/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22781841/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Moore%20LD,%20Le%20T,%20Fan%20G.%20DNA%20methylation%20and%20its%20basic%20function.%20Neuropsychopharmacology.%202013;38(1):23%E2%80%9338." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR38">
<span class="label">38.</span><cite>Yang X, Han H, De Carvalho DD, Lay FD, Jones PA, Liang G. Gene body methylation can alter gene expression and is a therapeutic target in cancer. Cancer Cell. 2014;26(4):577–90.
</cite> [<a href="https://doi.org/10.1016/j.ccr.2014.07.028" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4224113/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25263941/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yang%20X,%20Han%20H,%20De%20Carvalho%20DD,%20Lay%20FD,%20Jones%20PA,%20Liang%20G.%20Gene%20body%20methylation%20can%20alter%20gene%20expression%20and%20is%20a%20therapeutic%20target%20in%20cancer.%20Cancer%20Cell.%202014;26(4):577%E2%80%9390." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR39">
<span class="label">39.</span><cite>Zhang L, Lu Q, Chang C. Epigenetics in Health and Disease. Adv Exp Med Biol. 2020;1253:3–55.
</cite> [<a href="https://doi.org/10.1007/978-981-15-3449-2_1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32445090/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhang%20L,%20Lu%20Q,%20Chang%20C.%20Epigenetics%20in%20Health%20and%20Disease.%20Adv%20Exp%20Med%20Biol.%202020;1253:3%E2%80%9355." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR40">
<span class="label">40.</span><cite>Portela A, Esteller M. Epigenetic modifications and human disease. Nat Biotechnol. 2010;28(10):1057–68.
</cite> [<a href="https://doi.org/10.1038/nbt.1685" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20944598/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Portela%20A,%20Esteller%20M.%20Epigenetic%20modifications%20and%20human%20disease.%20Nat%20Biotechnol.%202010;28(10):1057%E2%80%9368." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR41">
<span class="label">41.</span><cite>Kulis M, Esteller M. DNA methylation and cancer. Adv Genet. 2010;70:27–56.
</cite> [<a href="https://doi.org/10.1016/B978-0-12-380866-0.60002-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20920744/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kulis%20M,%20Esteller%20M.%20DNA%20methylation%20and%20cancer.%20Adv%20Genet.%202010;70:27%E2%80%9356." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR42">
<span class="label">42.</span><cite>Beier V, Mund C, Hoheisel JD. Monitoring methylation changes in cancer. Adv Biochem Eng Biotechnol. 2007;104:1–11.
</cite> [<a href="https://doi.org/10.1007/10_024" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17290816/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Beier%20V,%20Mund%20C,%20Hoheisel%20JD.%20Monitoring%20methylation%20changes%20in%20cancer.%20Adv%20Biochem%20Eng%20Biotechnol.%202007;104:1%E2%80%9311." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR43">
<span class="label">43.</span><cite>Romero-Garcia S, Prado-Garcia H, Carlos-Reyes A. Role of DNA methylation in the resistance to therapy in solid tumors. Front Oncol. 2020;10:1152.
</cite> [<a href="https://doi.org/10.3389/fonc.2020.01152" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7426728/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32850327/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Romero-Garcia%20S,%20Prado-Garcia%20H,%20Carlos-Reyes%20A.%20Role%20of%20DNA%20methylation%20in%20the%20resistance%20to%20therapy%20in%20solid%20tumors.%20Front%20Oncol.%202020;10:1152." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR44">
<span class="label">44.</span><cite>Jostes S, Nettersheim D, Schorle H. Epigenetic drugs and their molecular targets in testicular germ cell tumours. Nat Rev Urol. 2019;16(4):245–59.
</cite> [<a href="https://doi.org/10.1038/s41585-019-0154-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30765888/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Jostes%20S,%20Nettersheim%20D,%20Schorle%20H.%20Epigenetic%20drugs%20and%20their%20molecular%20targets%20in%20testicular%20germ%20cell%20tumours.%20Nat%20Rev%20Urol.%202019;16(4):245%E2%80%9359." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR45">
<span class="label">45.</span><cite>Xylinas E, Hassler MR, Zhuang D, et al. An epigenomic approach to improving response to neoadjuvant cisplatin chemotherapy in bladder cancer. Biomolecules. 2016;6(3):37.
</cite> [<a href="https://doi.org/10.3390/biom6030037" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5039423/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27598218/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Xylinas%20E,%20Hassler%20MR,%20Zhuang%20D,%20et%20al.%20An%20epigenomic%20approach%20to%20improving%20response%20to%20neoadjuvant%20cisplatin%20chemotherapy%20in%20bladder%20cancer.%20Biomolecules.%202016;6(3):37." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR46">
<span class="label">46.</span><cite>Zhang YW, Zheng Y, Wang JZ, et al. Integrated analysis of DNA methylation and mRNA expression profiling reveals candidate genes associated with cisplatin resistance in non-small cell lung cancer. Epigenetics. 2014;9(6):896–909.
</cite> [<a href="https://doi.org/10.4161/epi.28601" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4065187/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24699858/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhang%20YW,%20Zheng%20Y,%20Wang%20JZ,%20et%20al.%20Integrated%20analysis%20of%20DNA%20methylation%20and%20mRNA%20expression%20profiling%20reveals%20candidate%20genes%20associated%20with%20cisplatin%20resistance%20in%20non-small%20cell%20lung%20cancer.%20Epigenetics.%202014;9(6):896%E2%80%93909." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR47">
<span class="label">47.</span><cite>Conrad M. NNT in NSCLC: No need to worry? J Exp Med. 2020;217(6): e20200310.
</cite> [<a href="https://doi.org/10.1084/jem.20200310" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7971126/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32294154/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Conrad%20M.%20NNT%20in%20NSCLC:%20No%20need%20to%20worry?%20J%20Exp%20Med.%202020;217(6):%20e20200310." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR48">
<span class="label">48.</span><cite>Xu C, Jiang S, Ma X, et al. CRISPR-based DNA methylation editing of NNT rescues the cisplatin resistance of lung cancer cells by reducing autophagy. Arch Toxicol. 2023;97(2):441–56.
</cite> [<a href="https://doi.org/10.1007/s00204-022-03404-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36336710/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Xu%20C,%20Jiang%20S,%20Ma%20X,%20et%20al.%20CRISPR-based%20DNA%20methylation%20editing%20of%20NNT%20rescues%20the%20cisplatin%20resistance%20of%20lung%20cancer%20cells%20by%20reducing%20autophagy.%20Arch%20Toxicol.%202023;97(2):441%E2%80%9356." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR49">
<span class="label">49.</span><cite>Lu CW, Zhou DD, Xie T, et al. HOXA11 antisense long noncoding RNA (HOXA11-AS): a promising lncRNA in human cancers. Cancer Med. 2018;7(8):3792–9.
</cite> [<a href="https://doi.org/10.1002/cam4.1571" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6089141/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29992790/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lu%20CW,%20Zhou%20DD,%20Xie%20T,%20et%20al.%20HOXA11%20antisense%20long%20noncoding%20RNA%20(HOXA11-AS):%20a%20promising%20lncRNA%20in%20human%20cancers.%20Cancer%20Med.%202018;7(8):3792%E2%80%939." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR50">
<span class="label">50.</span><cite>Zhang Y, Yuan Y, Li Y, Zhang P, Chen P, Sun S. An inverse interaction between HOXA11 and HOXA11-AS is associated with cisplatin resistance in lung adenocarcinoma. Epigenetics. 2019;14(10):949–60.
</cite> [<a href="https://doi.org/10.1080/15592294.2019.1625673" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6691981/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31144606/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhang%20Y,%20Yuan%20Y,%20Li%20Y,%20Zhang%20P,%20Chen%20P,%20Sun%20S.%20An%20inverse%20interaction%20between%20HOXA11%20and%20HOXA11-AS%20is%20associated%20with%20cisplatin%20resistance%20in%20lung%20adenocarcinoma.%20Epigenetics.%202019;14(10):949%E2%80%9360." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR51">
<span class="label">51.</span><cite>Beretta GL, Alampi D, Corno C, Carenini N, Corna E, Perego P. Kiss-1 modulation by epigenetic agents improves the cisplatin sensitivity of lung cancer cells. Int J Mol Sci. 2024;25(9): 5048.
</cite> [<a href="https://doi.org/10.3390/ijms25095048" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11084743/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38732265/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Beretta%20GL,%20Alampi%20D,%20Corno%20C,%20Carenini%20N,%20Corna%20E,%20Perego%20P.%20Kiss-1%20modulation%20by%20epigenetic%20agents%20improves%20the%20cisplatin%20sensitivity%20of%20lung%20cancer%20cells.%20Int%20J%20Mol%20Sci.%202024;25(9):%205048." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR52">
<span class="label">52.</span><cite>Liu XS, Wu H, Ji X, et al. Editing DNA Methylation in the Mammalian Genome. Cell. 2016;167(1):233–47.
</cite> [<a href="https://doi.org/10.1016/j.cell.2016.08.056" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5062609/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27662091/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Liu%20XS,%20Wu%20H,%20Ji%20X,%20et%20al.%20Editing%20DNA%20Methylation%20in%20the%20Mammalian%20Genome.%20Cell.%202016;167(1):233%E2%80%9347." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR53">
<span class="label">53.</span><cite>Jin Z, Zhao L, Chang Y, et al. Crtac1 enhances the chemosensitivity of non-small cell lung cancer to cisplatin by eliciting RyR-mediated calcium release and inhibiting Akt1 expression. Cell Death Dis. 2023;14(8):563.
</cite> [<a href="https://doi.org/10.1038/s41419-023-06088-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10460435/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37633993/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Jin%20Z,%20Zhao%20L,%20Chang%20Y,%20et%20al.%20Crtac1%20enhances%20the%20chemosensitivity%20of%20non-small%20cell%20lung%20cancer%20to%20cisplatin%20by%20eliciting%20RyR-mediated%20calcium%20release%20and%20inhibiting%20Akt1%20expression.%20Cell%20Death%20Dis.%202023;14(8):563." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR54">
<span class="label">54.</span><cite>Ibanez de Caceres I, CortesSempere M, Moratilla C, et al. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer. Oncogene. 2010;29(11):1681–90.
</cite> [<a href="https://doi.org/10.1038/onc.2009.454" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20023704/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ibanez%20de%20Caceres%20I,%20CortesSempere%20M,%20Moratilla%20C,%20et%20al.%20IGFBP-3%20hypermethylation-derived%20deficiency%20mediates%20cisplatin%20resistance%20in%20non-small-cell%20lung%20cancer.%20Oncogene.%202010;29(11):1681%E2%80%9390." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR55">
<span class="label">55.</span><cite>Wang Y, Zhang L, Yang J, et al. CDH13 promoter methylation regulates cisplatin resistance of non-small cell lung cancer cells. Oncol Lett. 2018;16(5):5715–22.
</cite> [<a href="https://doi.org/10.3892/ol.2018.9325" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6176259/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30344726/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wang%20Y,%20Zhang%20L,%20Yang%20J,%20et%20al.%20CDH13%20promoter%20methylation%20regulates%20cisplatin%20resistance%20of%20non-small%20cell%20lung%20cancer%20cells.%20Oncol%20Lett.%202018;16(5):5715%E2%80%9322." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR56">
<span class="label">56.</span><cite>Lu TX, Rothenberg ME. MicroRNA. J Allergy Clin Immunol. 2018;141(4):1202–7.
</cite> [<a href="https://doi.org/10.1016/j.jaci.2017.08.034" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5889965/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29074454/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lu%20TX,%20Rothenberg%20ME.%20MicroRNA.%20J%20Allergy%20Clin%20Immunol.%202018;141(4):1202%E2%80%937." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR57">
<span class="label">57.</span><cite>Fojo T. Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs. Drug Resist Updat. 2007;10(1–2):59–67.
</cite> [<a href="https://doi.org/10.1016/j.drup.2007.02.002" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17350322/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Fojo%20T.%20Multiple%20paths%20to%20a%20drug%20resistance%20phenotype:%20mutations,%20translocations,%20deletions%20and%20amplification%20of%20coding%20genes%20or%20promoter%20regions,%20epigenetic%20changes%20and%20microRNAs.%20Drug%20Resist%20Updat.%202007;10(1%E2%80%932):59%E2%80%9367." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR58">
<span class="label">58.</span><cite>Berindan-Neagoe I, Monroig Pdel C, Pasculli B, Calin GA. Micrornaome genome: a treasure for cancer diagnosis and therapy. CA Cancer J Clin. 2014;64(5):311–36.
</cite> [<a href="https://doi.org/10.3322/caac.21244" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4461198/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25104502/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Berindan-Neagoe%20I,%20Monroig%20Pdel%20C,%20Pasculli%20B,%20Calin%20GA.%20Micrornaome%20genome:%20a%20treasure%20for%20cancer%20diagnosis%20and%20therapy.%20CA%20Cancer%20J%20Clin.%202014;64(5):311%E2%80%9336." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR59">
<span class="label">59.</span><cite>Van Roosbroeck K, Fanini F, Setoyama T, et al. Combining anti-Mir-155 with chemotherapy for the treatment of lung cancers. Clin Cancer Res. 2017;23(11):2891–904.
</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-16-1025" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5449263/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27903673/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Van%20Roosbroeck%20K,%20Fanini%20F,%20Setoyama%20T,%20et%20al.%20Combining%20anti-Mir-155%20with%20chemotherapy%20for%20the%20treatment%20of%20lung%20cancers.%20Clin%20Cancer%20Res.%202017;23(11):2891%E2%80%93904." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR60">
<span class="label">60.</span><cite>Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol. 2010;2(1): a001008.
</cite> [<a href="https://doi.org/10.1101/cshperspect.a001008" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2827900/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20182602/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Olivier%20M,%20Hollstein%20M,%20Hainaut%20P.%20TP53%20mutations%20in%20human%20cancers:%20origins,%20consequences,%20and%20clinical%20use.%20Cold%20Spring%20Harb%20Perspect%20Biol.%202010;2(1):%20a001008." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR61">
<span class="label">61.</span><cite>Fang C, et al. MiR-488 inhibits proliferation and cisplatin sensibility in non-small-cell lung cancer (NSCLC) cells by activating the eIF3a-mediated NER signaling pathway. Sci Rep. 2017;7(1):40384.
</cite> [<a href="https://doi.org/10.1038/srep40384" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5225486/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28074905/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Fang%20C,%20et%20al.%20MiR-488%20inhibits%20proliferation%20and%20cisplatin%20sensibility%20in%20non-small-cell%20lung%20cancer%20(NSCLC)%20cells%20by%20activating%20the%20eIF3a-mediated%20NER%20signaling%20pathway.%20Sci%20Rep.%202017;7(1):40384." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR62">
<span class="label">62.</span><cite>Seidl C, Panzitt K, Bertsch A, et al. Microrna-182-5p regulates hedgehog signaling pathway and chemosensitivity of cisplatin-resistant lung adenocarcinoma cells via targeting GLI2. Cancer Lett. 2020;469:266–76.
</cite> [<a href="https://doi.org/10.1016/j.canlet.2019.10.044" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31697978/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Seidl%20C,%20Panzitt%20K,%20Bertsch%20A,%20et%20al.%20Microrna-182-5p%20regulates%20hedgehog%20signaling%20pathway%20and%20chemosensitivity%20of%20cisplatin-resistant%20lung%20adenocarcinoma%20cells%20via%20targeting%20GLI2.%20Cancer%20Lett.%202020;469:266%E2%80%9376." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR63">
<span class="label">63.</span><cite>Shen D, Xia Y, Fu Y, et al. Hedgehog pathway and cancer: a new area (Review). Oncol Rep. 2024;52(3):116.
</cite> [<a href="https://doi.org/10.3892/or.2024.8775" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11267502/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38994763/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Shen%20D,%20Xia%20Y,%20Fu%20Y,%20et%20al.%20Hedgehog%20pathway%20and%20cancer:%20a%20new%20area%20(Review).%20Oncol%20Rep.%202024;52(3):116." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR64">
<span class="label">64.</span><cite>Wu H, Mu X, Liu L, et al. Bone marrow mesenchymal stem cells-derived exosomal microRNA-193a reduces cisplatin resistance of non-small cell lung cancer cells via targeting LRRC1. Cell Death Dis. 2020;11(9):801.
</cite> [<a href="https://doi.org/10.1038/s41419-020-02962-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7519084/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32978367/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wu%20H,%20Mu%20X,%20Liu%20L,%20et%20al.%20Bone%20marrow%20mesenchymal%20stem%20cells-derived%20exosomal%20microRNA-193a%20reduces%20cisplatin%20resistance%20of%20non-small%20cell%20lung%20cancer%20cells%20via%20targeting%20LRRC1.%20Cell%20Death%20Dis.%202020;11(9):801." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR65">
<span class="label">65.</span><cite>Zhang J, Hua X, Qi N, et al. Mir-27b suppresses epithelial-mesenchymal transition and chemoresistance in lung cancer by targeting Snail1. Life Sci. 2020;254: 117238.
</cite> [<a href="https://doi.org/10.1016/j.lfs.2019.117238" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31887300/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhang%20J,%20Hua%20X,%20Qi%20N,%20et%20al.%20Mir-27b%20suppresses%20epithelial-mesenchymal%20transition%20and%20chemoresistance%20in%20lung%20cancer%20by%20targeting%20Snail1.%20Life%20Sci.%202020;254:%20117238." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR66">
<span class="label">66.</span><cite>Sun DM, Tang BF, Li ZX, et al. MiR-29c reduces the cisplatin resistance of non-small cell lung cancer cells by negatively regulating the PI3K/Akt pathway. Sci Rep. 2018;8(1):8007.
</cite> [<a href="https://doi.org/10.1038/s41598-018-26381-w" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5964122/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29789623/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Sun%20DM,%20Tang%20BF,%20Li%20ZX,%20et%20al.%20MiR-29c%20reduces%20the%20cisplatin%20resistance%20of%20non-small%20cell%20lung%20cancer%20cells%20by%20negatively%20regulating%20the%20PI3K/Akt%20pathway.%20Sci%20Rep.%202018;8(1):8007." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR67">
<span class="label">67.</span><cite>Huang G, Lou T, Pan J, et al. Mir-204 reduces cisplatin resistance in non-small cell lung cancer through suppression of the caveolin-1/AKT/Bad pathway. Aging (Albany NY). 2019;11(7):2138–50.
</cite> [<a href="https://doi.org/10.18632/aging.101907" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6503872/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30981205/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Huang%20G,%20Lou%20T,%20Pan%20J,%20et%20al.%20Mir-204%20reduces%20cisplatin%20resistance%20in%20non-small%20cell%20lung%20cancer%20through%20suppression%20of%20the%20caveolin-1/AKT/Bad%20pathway.%20Aging%20(Albany%20NY).%202019;11(7):2138%E2%80%9350." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR68">
<span class="label">68.</span><cite>Zeng F, Wang Q, Wang S, et al. Linc00173 promotes chemoresistance and progression of small cell lung cancer by sponging miR-218 to regulate Etk expression. Oncogene. 2020;39(2):293–307.
</cite> [<a href="https://doi.org/10.1038/s41388-019-0984-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31477834/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zeng%20F,%20Wang%20Q,%20Wang%20S,%20et%20al.%20Linc00173%20promotes%20chemoresistance%20and%20progression%20of%20small%20cell%20lung%20cancer%20by%20sponging%20miR-218%20to%20regulate%20Etk%20expression.%20Oncogene.%202020;39(2):293%E2%80%93307." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR69">
<span class="label">69.</span><cite>Herman AB, Tsitsipatis D, Gorospe M. Integrated lncRNA function upon genomic and epigenomic regulation. Mol Cell. 2022;82(12):2252–66.
</cite> [<a href="https://doi.org/10.1016/j.molcel.2022.05.027" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9219586/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35714586/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Herman%20AB,%20Tsitsipatis%20D,%20Gorospe%20M.%20Integrated%20lncRNA%20function%20upon%20genomic%20and%20epigenomic%20regulation.%20Mol%20Cell.%202022;82(12):2252%E2%80%9366." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR70">
<span class="label">70.</span><cite>Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet. 2009;10(3):155–9.
</cite> [<a href="https://doi.org/10.1038/nrg2521" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19188922/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Mercer%20TR,%20Dinger%20ME,%20Mattick%20JS.%20Long%20non-coding%20RNAs:%20insights%20into%20functions.%20Nat%20Rev%20Genet.%202009;10(3):155%E2%80%939." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR71">
<span class="label">71.</span><cite>Bhan A, Soleimani M, Mandal SS. Long noncoding RNA and cancer: a new paradigm. Cancer Res. 2017;77(15):3965–81.
</cite> [<a href="https://doi.org/10.1158/0008-5472.CAN-16-2634" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8330958/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28701486/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Bhan%20A,%20Soleimani%20M,%20Mandal%20SS.%20Long%20noncoding%20RNA%20and%20cancer:%20a%20new%20paradigm.%20Cancer%20Res.%202017;77(15):3965%E2%80%9381." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR72">
<span class="label">72.</span><cite>Fu J, Pan J, Yang X, et al. Mechanistic study of lncRNA UCA1 promoting growth and cisplatin resistance in lung adenocarcinoma. Cancer Cell Int. 2021;21(1):505.
</cite> [<a href="https://doi.org/10.1186/s12935-021-02207-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8454127/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34544452/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Fu%20J,%20Pan%20J,%20Yang%20X,%20et%20al.%20Mechanistic%20study%20of%20lncRNA%20UCA1%20promoting%20growth%20and%20cisplatin%20resistance%20in%20lung%20adenocarcinoma.%20Cancer%20Cell%20Int.%202021;21(1):505." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR73">
<span class="label">73.</span><cite>Li Z, Niu H, Qin Q, et al. LncRNA UCA1 mediates resistance to cisplatin by regulating the miR-143/FOSL2-signaling pathway in ovarian cancer. Mol Ther. 2019;17:92–101.</cite> [<a href="https://doi.org/10.1016/j.omtn.2019.05.007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6595407/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31234009/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Li%20Z,%20Niu%20H,%20Qin%20Q,%20et%20al.%20LncRNA%20UCA1%20mediates%20resistance%20to%20cisplatin%20by%20regulating%20the%20miR-143/FOSL2-signaling%20pathway%20in%20ovarian%20cancer.%20Mol%20Ther.%202019;17:92%E2%80%93101." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR74">
<span class="label">74.</span><cite>Chong ZX, Ho WY, Yeap SK. Tumour-regulatory role of long non-coding RNA HOXA-AS3. Prog Biophys Mol Biol. 2024;189:13–25.
</cite> [<a href="https://doi.org/10.1016/j.pbiomolbio.2024.04.003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38593905/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chong%20ZX,%20Ho%20WY,%20Yeap%20SK.%20Tumour-regulatory%20role%20of%20long%20non-coding%20RNA%20HOXA-AS3.%20Prog%20Biophys%20Mol%20Biol.%202024;189:13%E2%80%9325." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR75">
<span class="label">75.</span><cite>Zhang H, Liu Y, Yan L, et al. Increased levels of the long noncoding RNA, HOXA-AS3, promote proliferation of A549 cells. Cell Death Dis. 2018;9(6):707.
</cite> [<a href="https://doi.org/10.1038/s41419-018-0725-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5999602/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29899328/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhang%20H,%20Liu%20Y,%20Yan%20L,%20et%20al.%20Increased%20levels%20of%20the%20long%20noncoding%20RNA,%20HOXA-AS3,%20promote%20proliferation%20of%20A549%20cells.%20Cell%20Death%20Dis.%202018;9(6):707." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR76">
<span class="label">76.</span><cite>Lin S, Zhang R, An X, et al. LncRNA HOXA-AS3 confers cisplatin resistance by interacting with HOXA3 in non-small-cell lung carcinoma cells. Oncogenesis. 2019;8(11):60.
</cite> [<a href="https://doi.org/10.1038/s41389-019-0170-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6794325/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31615976/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lin%20S,%20Zhang%20R,%20An%20X,%20et%20al.%20LncRNA%20HOXA-AS3%20confers%20cisplatin%20resistance%20by%20interacting%20with%20HOXA3%20in%20non-small-cell%20lung%20carcinoma%20cells.%20Oncogenesis.%202019;8(11):60." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR77">
<span class="label">77.</span><cite>Ebrahimnezhad M, Asl SH, Rezaie M, Molavand M, Yousefi B, Majidinia M. LncRNAs: new players of cancer drug resistance via targeting ABC transporters. IUBMB Life. 2024;76(11):883–921.
</cite> [<a href="https://doi.org/10.1002/iub.2888" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39091106/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ebrahimnezhad%20M,%20Asl%20SH,%20Rezaie%20M,%20Molavand%20M,%20Yousefi%20B,%20Majidinia%20M.%20LncRNAs:%20new%20players%20of%20cancer%20drug%20resistance%20via%20targeting%20ABC%20transporters.%20IUBMB%20Life.%202024;76(11):883%E2%80%93921." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR78">
<span class="label">78.</span><cite>Zhang H, Luo Y, Xu W, Li K, Liao C. Silencing long intergenic non-coding RNA 00707 enhances cisplatin sensitivity in cisplatin-resistant non-small-cell lung cancer cells by sponging miR-145. Oncol Lett. 2019;18(6):6261–8.
</cite> [<a href="https://doi.org/10.3892/ol.2019.10959" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6865129/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31788103/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhang%20H,%20Luo%20Y,%20Xu%20W,%20Li%20K,%20Liao%20C.%20Silencing%20long%20intergenic%20non-coding%20RNA%2000707%20enhances%20cisplatin%20sensitivity%20in%20cisplatin-resistant%20non-small-cell%20lung%20cancer%20cells%20by%20sponging%20miR-145.%20Oncol%20Lett.%202019;18(6):6261%E2%80%938." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR79">
<span class="label">79.</span><cite>Goyal B, Yadav SRM, Awasthee N, Gupta S, Kunnumakkara AB, Gupta SC. Diagnostic, prognostic, and therapeutic significance of long non-coding RNA MALAT1 in cancer. Biochimica et Biophysica Acta (BBA). 2021;1875(2): 188502.</cite> [<a href="https://doi.org/10.1016/j.bbcan.2021.188502" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33428963/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Goyal%20B,%20Yadav%20SRM,%20Awasthee%20N,%20Gupta%20S,%20Kunnumakkara%20AB,%20Gupta%20SC.%20Diagnostic,%20prognostic,%20and%20therapeutic%20significance%20of%20long%20non-coding%20RNA%20MALAT1%20in%20cancer.%20Biochimica%20et%20Biophysica%20Acta%20(BBA).%202021;1875(2):%20188502." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR80">
<span class="label">80.</span><cite>Zhang X, He X, Liu Y, et al. MiR-101-3p inhibits the growth and metastasis of non-small cell lung cancer through blocking PI3K/AKT signal pathway by targeting MALAT-1. Biomed Pharmacother. 2017;93:1065–73.
</cite> [<a href="https://doi.org/10.1016/j.biopha.2017.07.005" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28738500/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhang%20X,%20He%20X,%20Liu%20Y,%20et%20al.%20MiR-101-3p%20inhibits%20the%20growth%20and%20metastasis%20of%20non-small%20cell%20lung%20cancer%20through%20blocking%20PI3K/AKT%20signal%20pathway%20by%20targeting%20MALAT-1.%20Biomed%20Pharmacother.%202017;93:1065%E2%80%9373." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR81">
<span class="label">81.</span><cite>Fang Z, Chen W, Yuan Z, Liu X, Jiang H. LncRNA-MALAT1 contributes to the cisplatin-resistance of lung cancer by upregulating MRP1 and MDR1 via STAT3 activation. Biomed Pharmacother. 2018;101:536–42.
</cite> [<a href="https://doi.org/10.1016/j.biopha.2018.02.130" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29505924/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Fang%20Z,%20Chen%20W,%20Yuan%20Z,%20Liu%20X,%20Jiang%20H.%20LncRNA-MALAT1%20contributes%20to%20the%20cisplatin-resistance%20of%20lung%20cancer%20by%20upregulating%20MRP1%20and%20MDR1%20via%20STAT3%20activation.%20Biomed%20Pharmacother.%202018;101:536%E2%80%9342." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR82">
<span class="label">82.</span><cite>Chen W, Zhao W, Zhang L, et al. MALAT1-miR-101-SOX9 feedback loop modulates the chemo-resistance of lung cancer cell to DDP via Wnt signaling pathway. Oncotarget. 2017;8(55):94317–29.
</cite> [<a href="https://doi.org/10.18632/oncotarget.21693" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5706876/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29212230/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chen%20W,%20Zhao%20W,%20Zhang%20L,%20et%20al.%20MALAT1-miR-101-SOX9%20feedback%20loop%20modulates%20the%20chemo-resistance%20of%20lung%20cancer%20cell%20to%20DDP%20via%20Wnt%20signaling%20pathway.%20Oncotarget.%202017;8(55):94317%E2%80%9329." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR83">
<span class="label">83.</span><cite>Roh J, Kim B, Im M, et al. MALAT1-regulated gene expression profiling in lung cancer cell lines. BMC Cancer. 2023;23(1):818.
</cite> [<a href="https://doi.org/10.1186/s12885-023-11347-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10476395/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37667226/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Roh%20J,%20Kim%20B,%20Im%20M,%20et%20al.%20MALAT1-regulated%20gene%20expression%20profiling%20in%20lung%20cancer%20cell%20lines.%20BMC%20Cancer.%202023;23(1):818." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR84">
<span class="label">84.</span><cite>Chen W, Tan X, Yang Q, Fang Z, Xu Y. MALAT1 enhances gemcitabine resistance in non-small cell lung cancer cells by directly affecting miR-27a-5p/PBOV1 axis. Cell Signal. 2022;94: 110326.
</cite> [<a href="https://doi.org/10.1016/j.cellsig.2022.110326" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35367362/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chen%20W,%20Tan%20X,%20Yang%20Q,%20Fang%20Z,%20Xu%20Y.%20MALAT1%20enhances%20gemcitabine%20resistance%20in%20non-small%20cell%20lung%20cancer%20cells%20by%20directly%20affecting%20miR-27a-5p/PBOV1%20axis.%20Cell%20Signal.%202022;94:%20110326." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR85">
<span class="label">85.</span><cite>Hou J, Zhang G, Wang X, Wang Y, Wang K. Functions and mechanisms of lncRNA MALAT1 in cancer chemotherapy resistance. Biomark Res. 2023;11(1):23.
</cite> [<a href="https://doi.org/10.1186/s40364-023-00467-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9960193/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36829256/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hou%20J,%20Zhang%20G,%20Wang%20X,%20Wang%20Y,%20Wang%20K.%20Functions%20and%20mechanisms%20of%20lncRNA%20MALAT1%20in%20cancer%20chemotherapy%20resistance.%20Biomark%20Res.%202023;11(1):23." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR86">
<span class="label">86.</span><cite>Zhou WY, Cai ZR, Liu J, Wang DS, Ju HQ, Xu RH. Circular RNA: metabolism, functions and interactions with proteins. Mol Cancer. 2020;19(1):172.
</cite> [<a href="https://doi.org/10.1186/s12943-020-01286-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7734744/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33317550/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhou%20WY,%20Cai%20ZR,%20Liu%20J,%20Wang%20DS,%20Ju%20HQ,%20Xu%20RH.%20Circular%20RNA:%20metabolism,%20functions%20and%20interactions%20with%20proteins.%20Mol%20Cancer.%202020;19(1):172." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR87">
<span class="label">87.</span><cite>Wang C, Liu WR, Tan S, et al. Characterization of distinct circular RNA signatures in solid tumors. Mol Cancer. 2022;21(1):63.
</cite> [<a href="https://doi.org/10.1186/s12943-022-01546-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8889743/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35236349/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wang%20C,%20Liu%20WR,%20Tan%20S,%20et%20al.%20Characterization%20of%20distinct%20circular%20RNA%20signatures%20in%20solid%20tumors.%20Mol%20Cancer.%202022;21(1):63." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR88">
<span class="label">88.</span><cite>Li J, Zhang Q, Jiang D, Shao J, Li W, Wang C. Circrnas in lung cancer- role and clinical application. Cancer Lett. 2022;544: 215810.
</cite> [<a href="https://doi.org/10.1016/j.canlet.2022.215810" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35780929/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Li%20J,%20Zhang%20Q,%20Jiang%20D,%20Shao%20J,%20Li%20W,%20Wang%20C.%20Circrnas%20in%20lung%20cancer-%20role%20and%20clinical%20application.%20Cancer%20Lett.%202022;544:%20215810." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR89">
<span class="label">89.</span><cite>Zhu Y, Liang L, Zhao Y, et al. Circnup50 is a novel therapeutic target that promotes cisplatin resistance in ovarian cancer by modulating p53 ubiquitination. J Nanobiotechnology. 2024;22(1): 35.
</cite> [<a href="https://doi.org/10.1186/s12951-024-02295-w" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10799427/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38243224/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhu%20Y,%20Liang%20L,%20Zhao%20Y,%20et%20al.%20Circnup50%20is%20a%20novel%20therapeutic%20target%20that%20promotes%20cisplatin%20resistance%20in%20ovarian%20cancer%20by%20modulating%20p53%20ubiquitination.%20J%20Nanobiotechnology.%202024;22(1):%2035." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR90">
<span class="label">90.</span><cite>Huang C, Yang Y, Wang X, et al. PTBP1-mediated biogenesis of circATIC promotes progression and cisplatin resistance of bladder cancer. Int J Biol Sci. 2024;20(9):3570–89.
</cite> [<a href="https://doi.org/10.7150/ijbs.96671" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11234215/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38993556/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Huang%20C,%20Yang%20Y,%20Wang%20X,%20et%20al.%20PTBP1-mediated%20biogenesis%20of%20circATIC%20promotes%20progression%20and%20cisplatin%20resistance%20of%20bladder%20cancer.%20Int%20J%20Biol%20Sci.%202024;20(9):3570%E2%80%9389." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR91">
<span class="label">91.</span><cite>Mu Q, Lv Y, Luo C, et al. Research progress on the functions and mechanism of circRNA in Cisplatin resistance in tumors. Front Pharmacol. 2021;12: 709324.
</cite> [<a href="https://doi.org/10.3389/fphar.2021.709324" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8458655/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34566636/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Mu%20Q,%20Lv%20Y,%20Luo%20C,%20et%20al.%20Research%20progress%20on%20the%20functions%20and%20mechanism%20of%20circRNA%20in%20Cisplatin%20resistance%20in%20tumors.%20Front%20Pharmacol.%202021;12:%20709324." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR92">
<span class="label">92.</span><cite>Zheng F, Xu R. CircPVT1 contributes to chemotherapy resistance of lung adenocarcinoma through miR-145-5p/ABCC1 axis. Biomed Pharmacother. 2020;124: 109828.
</cite> [<a href="https://doi.org/10.1016/j.biopha.2020.109828" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31986409/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zheng%20F,%20Xu%20R.%20CircPVT1%20contributes%20to%20chemotherapy%20resistance%20of%20lung%20adenocarcinoma%20through%20miR-145-5p/ABCC1%20axis.%20Biomed%20Pharmacother.%202020;124:%20109828." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR93">
<span class="label">93.</span><cite>Lu H, Xie X, Chen Q, et al. Clinical significance of circPVT1 in patients with non-small cell lung cancer who received cisplatin combined with gemcitabine chemotherapy. Tumori. 2021;107(3):204–8.
</cite> [<a href="https://doi.org/10.1177/0300891620941940" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32734834/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lu%20H,%20Xie%20X,%20Chen%20Q,%20et%20al.%20Clinical%20significance%20of%20circPVT1%20in%20patients%20with%20non-small%20cell%20lung%20cancer%20who%20received%20cisplatin%20combined%20with%20gemcitabine%20chemotherapy.%20Tumori.%202021;107(3):204%E2%80%938." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR94">
<span class="label">94.</span><cite>Li H, Liu F, Qin W. Circ_0072083 interference enhances growth-inhibiting effects of cisplatin in non-small-cell lung cancer cells via miR-545-3p/CBLL1 axis. Cancer Cell Int. 2020;20:78.
</cite> [<a href="https://doi.org/10.1186/s12935-020-1162-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7066755/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32190002/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Li%20H,%20Liu%20F,%20Qin%20W.%20Circ_0072083%20interference%20enhances%20growth-inhibiting%20effects%20of%20cisplatin%20in%20non-small-cell%20lung%20cancer%20cells%20via%20miR-545-3p/CBLL1%20axis.%20Cancer%20Cell%20Int.%202020;20:78." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR95">
<span class="label">95.</span><cite>Huang MS, Liu JY, Xia XB, et al. Hsa_circ_0001946 inhibits lung cancer progression and mediates cisplatin sensitivity in non-small cell lung cancer via the nucleotide excision repair signaling pathway. Front Oncol. 2019;9:508.
</cite> [<a href="https://doi.org/10.3389/fonc.2019.00508" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6582772/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31249811/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Huang%20MS,%20Liu%20JY,%20Xia%20XB,%20et%20al.%20Hsa_circ_0001946%20inhibits%20lung%20cancer%20progression%20and%20mediates%20cisplatin%20sensitivity%20in%20non-small%20cell%20lung%20cancer%20via%20the%20nucleotide%20excision%20repair%20signaling%20pathway.%20Front%20Oncol.%202019;9:508." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR96">
<span class="label">96.</span><cite>Zhang D, Ma Y, Ma Z, et al. Circular RNA SMARCA5 suppressed non-small cell lung cancer progression by regulating miR-670-5p/RBM24 axis. Acta Biochim Biophys Sin. 2020;52(10):1071–80.
</cite> [<a href="https://doi.org/10.1093/abbs/gmaa099" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33085761/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhang%20D,%20Ma%20Y,%20Ma%20Z,%20et%20al.%20Circular%20RNA%20SMARCA5%20suppressed%20non-small%20cell%20lung%20cancer%20progression%20by%20regulating%20miR-670-5p/RBM24%20axis.%20Acta%20Biochim%20Biophys%20Sin.%202020;52(10):1071%E2%80%9380." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR97">
<span class="label">97.</span><cite>Tong S. Circular RNA SMARCA5 may serve as a tumor suppressor in non-small cell lung cancer. J Clin Lab Anal. 2020;34(5): e23195.
</cite> [<a href="https://doi.org/10.1002/jcla.23195" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7246390/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31944395/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Tong%20S.%20Circular%20RNA%20SMARCA5%20may%20serve%20as%20a%20tumor%20suppressor%20in%20non-small%20cell%20lung%20cancer.%20J%20Clin%20Lab%20Anal.%202020;34(5):%20e23195." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR98">
<span class="label">98.</span><cite>Dong Y, Xu T, Zhong S, et al. Circ_0076305 regulates cisplatin resistance of non-small cell lung cancer via positively modulating STAT3 by sponging miR-296-5p. Life Sci. 2019;239: 116984.
</cite> [<a href="https://doi.org/10.1016/j.lfs.2019.116984" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31647948/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Dong%20Y,%20Xu%20T,%20Zhong%20S,%20et%20al.%20Circ_0076305%20regulates%20cisplatin%20resistance%20of%20non-small%20cell%20lung%20cancer%20via%20positively%20modulating%20STAT3%20by%20sponging%20miR-296-5p.%20Life%20Sci.%202019;239:%20116984." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR99">
<span class="label">99.</span><cite>Shao N, Song L, Sun X. Exosomal circ_PIP5K1A regulates the progression of non-small cell lung cancer and cisplatin sensitivity by miR-101/ABCC1 axis. Mol Cell Biochem. 2021;476(6):2253–67.
</cite> [<a href="https://doi.org/10.1007/s11010-021-04083-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33570734/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Shao%20N,%20Song%20L,%20Sun%20X.%20Exosomal%20circ_PIP5K1A%20regulates%20the%20progression%20of%20non-small%20cell%20lung%20cancer%20and%20cisplatin%20sensitivity%20by%20miR-101/ABCC1%20axis.%20Mol%20Cell%20Biochem.%202021;476(6):2253%E2%80%9367." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR100">
<span class="label">100.</span><cite>Skinner KT, Palkar AM, Hong AL. Genetics of ABCB1 in cancer. Cancers (Basel). 2023;15(17): 4236.
</cite> [<a href="https://doi.org/10.3390/cancers15174236" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10487083/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37686513/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Skinner%20KT,%20Palkar%20AM,%20Hong%20AL.%20Genetics%20of%20ABCB1%20in%20cancer.%20Cancers%20(Basel).%202023;15(17):%204236." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR101">
<span class="label">101.</span><cite>Mashouri L, Yousefi H, Aref AR, Ahadi AM, Molaei F, Alahari SK. Exosomes: composition, biogenesis, and mechanisms in cancer metastasis and drug resistance. Mol Cancer. 2019;18(1):75.
</cite> [<a href="https://doi.org/10.1186/s12943-019-0991-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6444571/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30940145/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Mashouri%20L,%20Yousefi%20H,%20Aref%20AR,%20Ahadi%20AM,%20Molaei%20F,%20Alahari%20SK.%20Exosomes:%20composition,%20biogenesis,%20and%20mechanisms%20in%20cancer%20metastasis%20and%20drug%20resistance.%20Mol%20Cancer.%202019;18(1):75." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR102">
<span class="label">102.</span><cite>Hong W, Xue M, Jiang J, Zhang Y, Gao X. Circular RNA circ-CPA4/ let-7 miRNA/PD-L1 axis regulates cell growth, stemness, drug resistance and immune evasion in non-small cell lung cancer (NSCLC). J Exp Clin Cancer Res. 2020;39(1):149.
</cite> [<a href="https://doi.org/10.1186/s13046-020-01648-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7397626/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32746878/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hong%20W,%20Xue%20M,%20Jiang%20J,%20Zhang%20Y,%20Gao%20X.%20Circular%20RNA%20circ-CPA4/%20let-7%20miRNA/PD-L1%20axis%20regulates%20cell%20growth,%20stemness,%20drug%20resistance%20and%20immune%20evasion%20in%20non-small%20cell%20lung%20cancer%20(NSCLC).%20J%20Exp%20Clin%20Cancer%20Res.%202020;39(1):149." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>] [<a href="/articles/PMC12341128/" class="text-red">Retracted</a>]</li>
<li id="CR103">
<span class="label">103.</span><cite>Zhao Y, Lu G, Ke X, et al. Mir-488 acts as a tumor suppressor gene in gastric cancer. Tumour Biol. 2016;37(7):8691–8.
</cite> [<a href="https://doi.org/10.1007/s13277-015-4645-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26738864/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhao%20Y,%20Lu%20G,%20Ke%20X,%20et%20al.%20Mir-488%20acts%20as%20a%20tumor%20suppressor%20gene%20in%20gastric%20cancer.%20Tumour%20Biol.%202016;37(7):8691%E2%80%938." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR104">
<span class="label">104.</span><cite>Zhao X, Li X, Zhou L, et al. LncRNA HOXA11-AS drives cisplatin resistance of human LUAD cells via modulating miR-454-3p/Stat3. Cancer Sci. 2018;109(10):3068–79.
</cite> [<a href="https://doi.org/10.1111/cas.13764" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6172072/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30099826/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhao%20X,%20Li%20X,%20Zhou%20L,%20et%20al.%20LncRNA%20HOXA11-AS%20drives%20cisplatin%20resistance%20of%20human%20LUAD%20cells%20via%20modulating%20miR-454-3p/Stat3.%20Cancer%20Sci.%202018;109(10):3068%E2%80%9379." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR105">
<span class="label">105.</span><cite>Husmann D, Gozani O. Histone lysine methyltransferases in biology and disease. Nat Struct Mol Biol. 2019;26(10):880–9.
</cite> [<a href="https://doi.org/10.1038/s41594-019-0298-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6951022/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31582846/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Husmann%20D,%20Gozani%20O.%20Histone%20lysine%20methyltransferases%20in%20biology%20and%20disease.%20Nat%20Struct%20Mol%20Biol.%202019;26(10):880%E2%80%939." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR106">
<span class="label">106.</span><cite>Jeon HY, Ryu H, Pornour M, Qi J. Histone demethylase JMJD1A in cancer progression and therapeutic resistance. Mol Carcinog. 2022;61(4):392–6.
</cite> [<a href="https://doi.org/10.1002/mc.23390" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8930527/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35020958/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Jeon%20HY,%20Ryu%20H,%20Pornour%20M,%20Qi%20J.%20Histone%20demethylase%20JMJD1A%20in%20cancer%20progression%20and%20therapeutic%20resistance.%20Mol%20Carcinog.%202022;61(4):392%E2%80%936." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR107">
<span class="label">107.</span><cite>Jarrold J, Davies CC. PRMTs and arginine methylation: cancer’s best-kept secret? Trends Mol Med. 2019;25(11):993–1009.
</cite> [<a href="https://doi.org/10.1016/j.molmed.2019.05.007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31230909/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Jarrold%20J,%20Davies%20CC.%20PRMTs%20and%20arginine%20methylation:%20cancer%E2%80%99s%20best-kept%20secret?%20Trends%20Mol%20Med.%202019;25(11):993%E2%80%931009." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR108">
<span class="label">108.</span><cite>Fan L, Sudeep K, Qi J. Histone Demethylase KDM3 (JMJD1) in Transcriptional Regulation and Cancer Progression. Adv Exp Med Biol. 2023;1433:69–86.
</cite> [<a href="https://doi.org/10.1007/978-3-031-38176-8_4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11052651/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37751136/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Fan%20L,%20Sudeep%20K,%20Qi%20J.%20Histone%20Demethylase%20KDM3%20(JMJD1)%20in%20Transcriptional%20Regulation%20and%20Cancer%20Progression.%20Adv%20Exp%20Med%20Biol.%202023;1433:69%E2%80%9386." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR109">
<span class="label">109.</span><cite>Shen X, Zhuang Z, Zhang Y, et al. JARID1B modulates lung cancer cell proliferation and invasion by regulating p53 expression. Tumour Biol. 2015;36(9):7133–42.
</cite> [<a href="https://doi.org/10.1007/s13277-015-3418-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25877751/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Shen%20X,%20Zhuang%20Z,%20Zhang%20Y,%20et%20al.%20JARID1B%20modulates%20lung%20cancer%20cell%20proliferation%20and%20invasion%20by%20regulating%20p53%20expression.%20Tumour%20Biol.%202015;36(9):7133%E2%80%9342." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR110">
<span class="label">110.</span><cite>Wang Y, Hou N, Cheng X, et al. Ezh2 acts as a tumor suppressor in Kras-driven lung adenocarcinoma. Int J Biol Sci. 2017;13(5):652–9.
</cite> [<a href="https://doi.org/10.7150/ijbs.19108" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5441181/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28539837/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wang%20Y,%20Hou%20N,%20Cheng%20X,%20et%20al.%20Ezh2%20acts%20as%20a%20tumor%20suppressor%20in%20Kras-driven%20lung%20adenocarcinoma.%20Int%20J%20Biol%20Sci.%202017;13(5):652%E2%80%939." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR111">
<span class="label">111.</span><cite>Watanabe H, Soejima K, Yasuda H, et al. Deregulation of histone lysine methyltransferases contributes to oncogenic transformation of human bronchoepithelial cells. Cancer Cell Int. 2008;8:15.
</cite> [<a href="https://doi.org/10.1186/1475-2867-8-15" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2584620/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18980680/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Watanabe%20H,%20Soejima%20K,%20Yasuda%20H,%20et%20al.%20Deregulation%20of%20histone%20lysine%20methyltransferases%20contributes%20to%20oncogenic%20transformation%20of%20human%20bronchoepithelial%20cells.%20Cancer%20Cell%20Int.%202008;8:15." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR112">
<span class="label">112.</span><cite>Zhang J, Zeng Y, Xing Y, et al. Myristoylation-mediated phase separation of EZH2 compartmentalizes STAT3 to promote lung cancer growth. Cancer Lett. 2021;516:84–98.
</cite> [<a href="https://doi.org/10.1016/j.canlet.2021.05.035" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34102285/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhang%20J,%20Zeng%20Y,%20Xing%20Y,%20et%20al.%20Myristoylation-mediated%20phase%20separation%20of%20EZH2%20compartmentalizes%20STAT3%20to%20promote%20lung%20cancer%20growth.%20Cancer%20Lett.%202021;516:84%E2%80%9398." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR113">
<span class="label">113.</span><cite>Cao Z, Wu W, Wei H, Zhang W, Huang Y, Dong Z. Downregulation of histone-lysine n-methyltransferase EZH2 inhibits cell viability and enhances chemosensitivity in lung cancer cells. Oncol Lett. 2021;21(1):26.
</cite> [<a href="https://doi.org/10.3892/ol.2020.12287" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7681225/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33240432/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Cao%20Z,%20Wu%20W,%20Wei%20H,%20Zhang%20W,%20Huang%20Y,%20Dong%20Z.%20Downregulation%20of%20histone-lysine%20n-methyltransferase%20EZH2%20inhibits%20cell%20viability%20and%20enhances%20chemosensitivity%20in%20lung%20cancer%20cells.%20Oncol%20Lett.%202021;21(1):26." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR114">
<span class="label">114.</span><cite>Liu H, Li W, Yu X, et al. EZH2-mediated Puma gene repression regulates non-small cell lung cancer cell proliferation and cisplatin-induced apoptosis. Oncotarget. 2016;7(35):56338–54.
</cite> [<a href="https://doi.org/10.18632/oncotarget.10841" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5302918/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27472460/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Liu%20H,%20Li%20W,%20Yu%20X,%20et%20al.%20EZH2-mediated%20Puma%20gene%20repression%20regulates%20non-small%20cell%20lung%20cancer%20cell%20proliferation%20and%20cisplatin-induced%20apoptosis.%20Oncotarget.%202016;7(35):56338%E2%80%9354." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR115">
<span class="label">115.</span><cite>Entezari M, Taheriazam A, Paskeh MDA, et al. The pharmacological and biological importance of EZH2 signaling in lung cancer. Biomed Pharmacother. 2023;160: 114313.
</cite> [<a href="https://doi.org/10.1016/j.biopha.2023.114313" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36738498/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Entezari%20M,%20Taheriazam%20A,%20Paskeh%20MDA,%20et%20al.%20The%20pharmacological%20and%20biological%20importance%20of%20EZH2%20signaling%20in%20lung%20cancer.%20Biomed%20Pharmacother.%202023;160:%20114313." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR116">
<span class="label">116.</span><cite>Wang Y, Guo Q, Huang Z, et al. Cell-free epigenomes enhanced fragmentomics-based model for early detection of lung cancer. Clin Transl Med. 2025;15(2):e702–25.</cite> [<a href="https://doi.org/10.1002/ctm2.70225" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11798665/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39909829/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wang%20Y,%20Guo%20Q,%20Huang%20Z,%20et%20al.%20Cell-free%20epigenomes%20enhanced%20fragmentomics-based%20model%20for%20early%20detection%20of%20lung%20cancer.%20Clin%20Transl%20Med.%202025;15(2):e702%E2%80%9325." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR117">
<span class="label">117.</span><cite>Zhu F, Yang X, Yang Y, et al. The role of histone methyltransferases in therapeutic resistance of NSCLC. Epigenetics. 2025;20(1):2536786.
</cite> [<a href="https://doi.org/10.1080/15592294.2025.2536786" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC12296068/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/40701777/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhu%20F,%20Yang%20X,%20Yang%20Y,%20et%20al.%20The%20role%20of%20histone%20methyltransferases%20in%20therapeutic%20resistance%20of%20NSCLC.%20Epigenetics.%202025;20(1):2536786." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR118">
<span class="label">118.</span><cite>Gardner EE, Lok BH, Schneeberger VE, et al. Chemosensitive relapse in small cell lung cancer proceeds through an EZH2-SLFN11 axis. Cancer Cell. 2017;31(2):286–99.
</cite> [<a href="https://doi.org/10.1016/j.ccell.2017.01.006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5313262/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28196596/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Gardner%20EE,%20Lok%20BH,%20Schneeberger%20VE,%20et%20al.%20Chemosensitive%20relapse%20in%20small%20cell%20lung%20cancer%20proceeds%20through%20an%20EZH2-SLFN11%20axis.%20Cancer%20Cell.%202017;31(2):286%E2%80%9399." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR119">
<span class="label">119.</span><cite>Yang D, Feng W, Zhuang Y, et al. Long non-coding RNA linc00665 inhibits CDKN1C expression by binding to EZH2 and affects cisplatin sensitivity of NSCLC cells. Mol Ther. 2021;23:1053–65.</cite> [<a href="https://doi.org/10.1016/j.omtn.2021.01.013" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7887328/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33664990/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yang%20D,%20Feng%20W,%20Zhuang%20Y,%20et%20al.%20Long%20non-coding%20RNA%20linc00665%20inhibits%20CDKN1C%20expression%20by%20binding%20to%20EZH2%20and%20affects%20cisplatin%20sensitivity%20of%20NSCLC%20cells.%20Mol%20Ther.%202021;23:1053%E2%80%9365." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR120">
<span class="label">120.</span><cite>Yang XJ, Seto E. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene. 2007;26(37):5310–8.
</cite> [<a href="https://doi.org/10.1038/sj.onc.1210599" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17694074/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yang%20XJ,%20Seto%20E.%20HATs%20and%20HDACs:%20from%20structure,%20function%20and%20regulation%20to%20novel%20strategies%20for%20therapy%20and%20prevention.%20Oncogene.%202007;26(37):5310%E2%80%938." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR121">
<span class="label">121.</span><cite>Wu D, Qiu Y, Jiao Y, Qiu Z, Liu D. Small molecules targeting HATs, HDACs, and BRDs in cancer therapy. Front Oncol. 2020;10: 560487.
</cite> [<a href="https://doi.org/10.3389/fonc.2020.560487" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7686570/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33262941/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wu%20D,%20Qiu%20Y,%20Jiao%20Y,%20Qiu%20Z,%20Liu%20D.%20Small%20molecules%20targeting%20HATs,%20HDACs,%20and%20BRDs%20in%20cancer%20therapy.%20Front%20Oncol.%202020;10:%20560487." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR122">
<span class="label">122.</span><cite>He Y, Chen D, Yi Y, et al. Histone deacetylase inhibitor sensitizes ERCC1-high non-small-cell lung cancer cells to cisplatin via regulating miR-149. Mol Ther. 2020;17:448–59.</cite> [<a href="https://doi.org/10.1016/j.omto.2020.05.001" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7251316/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32478168/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?He%20Y,%20Chen%20D,%20Yi%20Y,%20et%20al.%20Histone%20deacetylase%20inhibitor%20sensitizes%20ERCC1-high%20non-small-cell%20lung%20cancer%20cells%20to%20cisplatin%20via%20regulating%20miR-149.%20Mol%20Ther.%202020;17:448%E2%80%9359." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR123">
<span class="label">123.</span><cite>Fujita Y, Yagishita S, Hagiwara K, et al. The clinical relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 network in chemoresistant non-small-cell lung cancer. Mol Ther. 2015;23(4):717–27.
</cite> [<a href="https://doi.org/10.1038/mt.2015.10" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4395779/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25597412/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Fujita%20Y,%20Yagishita%20S,%20Hagiwara%20K,%20et%20al.%20The%20clinical%20relevance%20of%20the%20miR-197/CKS1B/STAT3-mediated%20PD-L1%20network%20in%20chemoresistant%20non-small-cell%20lung%20cancer.%20Mol%20Ther.%202015;23(4):717%E2%80%9327." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR124">
<span class="label">124.</span><cite>Wang H, Fu C, Du J, et al. Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells. J Exp Clin Cancer Res. 2020;39(1):29.
</cite> [<a href="https://doi.org/10.1186/s13046-020-1536-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7003365/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32024543/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wang%20H,%20Fu%20C,%20Du%20J,%20et%20al.%20Enhanced%20histone%20H3%20acetylation%20of%20the%20PD-L1%20promoter%20via%20the%20COP1/c-Jun/HDAC3%20axis%20is%20required%20for%20PD-L1%20expression%20in%20drug-resistant%20cancer%20cells.%20J%20Exp%20Clin%20Cancer%20Res.%202020;39(1):29." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR125">
<span class="label">125.</span><cite>Oerum S, Meynier V, Catala M, Tisné C. A comprehensive review of m6A/m6Am RNA methyltransferase structures. Nucleic Acids Res. 2021;49(13):7239–55.
</cite> [<a href="https://doi.org/10.1093/nar/gkab378" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8287941/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34023900/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Oerum%20S,%20Meynier%20V,%20Catala%20M,%20Tisn%C3%A9%20C.%20A%20comprehensive%20review%20of%20m6A/m6Am%20RNA%20methyltransferase%20structures.%20Nucleic%20Acids%20Res.%202021;49(13):7239%E2%80%9355." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR126">
<span class="label">126.</span><cite>He L, Li H, Wu A, Peng Y, Shu G, Yin G. Functions of N6-methyladenosine and its role in cancer. Mol Cancer. 2019;18(1):176. 10.1186/s12943-019-1109-9.
</cite> [<a href="https://doi.org/10.1186/s12943-019-1109-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6892141/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31801551/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?He%20L,%20Li%20H,%20Wu%20A,%20Peng%20Y,%20Shu%20G,%20Yin%20G.%20Functions%20of%20N6-methyladenosine%20and%20its%20role%20in%20cancer.%20Mol%20Cancer.%202019;18(1):176.%2010.1186/s12943-019-1109-9." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR127">
<span class="label">127.</span><cite>Yin H, Chen L, Piao S, et al. M6A RNA methylation-mediated RMRP stability renders proliferation and progression of non-small cell lung cancer through regulating TGFBR1/SMAD2/SMAD3 pathway [published correction appears in Cell Death Differ. 2023 Mar;30(3):856. 10.1038/s41418-022-01075-z]. Cell Death Differ. 2023;30(3):605–617.</cite>
</li>
<li id="CR128">
<span class="label">128.</span><cite>Song Z, Jia G, Ma P, Cang S. Exosomal miR-4443 promotes cisplatin resistance in non-small cell lung carcinoma by regulating FSP1 m6a modification-mediated ferroptosis. Life Sci. 2021;276: 119399.
</cite> [<a href="https://doi.org/10.1016/j.lfs.2021.119399" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33781830/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Song%20Z,%20Jia%20G,%20Ma%20P,%20Cang%20S.%20Exosomal%20miR-4443%20promotes%20cisplatin%20resistance%20in%20non-small%20cell%20lung%20carcinoma%20by%20regulating%20FSP1%20m6a%20modification-mediated%20ferroptosis.%20Life%20Sci.%202021;276:%20119399." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR129">
<span class="label">129.</span><cite>Jin D, Guo J, Wu Y, et al. M6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis. J Hematol Oncol. 2020;13(1):106.
</cite> [<a href="https://doi.org/10.1186/s13045-020-00942-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7397643/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32746876/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Jin%20D,%20Guo%20J,%20Wu%20Y,%20et%20al.%20M6A%20mRNA%20methylation%20initiated%20by%20METTL3%20directly%20promotes%20YAP%20translation%20and%20increases%20YAP%20activity%20by%20regulating%20the%20MALAT1-miR-1914-3p-YAP%20axis%20to%20induce%20NSCLC%20drug%20resistance%20and%20metastasis.%20J%20Hematol%20Oncol.%202020;13(1):106." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR130">
<span class="label">130.</span><cite>Yu F, Zheng S, Yu C, et al. <em>KRAS</em> mutants confer platinum resistance by regulating ALKBH5 posttranslational modifications in lung cancer. J Clin Invest. 2025;135(6): e185149.
</cite> [<a href="https://doi.org/10.1172/JCI185149" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11910214/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39960727/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yu%20F,%20Zheng%20S,%20Yu%20C,%20et%20al.%20KRAS%20mutants%20confer%20platinum%20resistance%20by%20regulating%20ALKBH5%20posttranslational%20modifications%20in%20lung%20cancer.%20J%20Clin%20Invest.%202025;135(6):%20e185149." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR131">
<span class="label">131.</span><cite>Fan W, Huang J, Tian F, et al. M6A-modified SNRPA controls alternative splicing of ERCC1 exon 8 to induce cisplatin resistance in lung adenocarcinoma. Adv Sci. 2024;11(47): e2404609.</cite> [<a href="https://doi.org/10.1002/advs.202404609" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11653629/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39555714/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Fan%20W,%20Huang%20J,%20Tian%20F,%20et%20al.%20M6A-modified%20SNRPA%20controls%20alternative%20splicing%20of%20ERCC1%20exon%208%20to%20induce%20cisplatin%20resistance%20in%20lung%20adenocarcinoma.%20Adv%20Sci.%202024;11(47):%20e2404609." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR132">
<span class="label">132.</span><cite>Juergens RA, Wrangle J, Vendetti FP, et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov. 2011;1(7):598–607.
</cite> [<a href="https://doi.org/10.1158/2159-8290.CD-11-0214" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3353724/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22586682/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Juergens%20RA,%20Wrangle%20J,%20Vendetti%20FP,%20et%20al.%20Combination%20epigenetic%20therapy%20has%20efficacy%20in%20patients%20with%20refractory%20advanced%20non-small%20cell%20lung%20cancer.%20Cancer%20Discov.%202011;1(7):598%E2%80%93607." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR133">
<span class="label">133.</span><cite>Morgensztern D, Cobo M, Ponce Aix S, et al. ABOUND. 2L+: A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC). Cancer. 2018;124(24):4667–75.
</cite> [<a href="https://doi.org/10.1002/cncr.31779" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30383906/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Morgensztern%20D,%20Cobo%20M,%20Ponce%20Aix%20S,%20et%20al.%20ABOUND.%202L+:%20A%20randomized%20phase%202%20study%20of%20nanoparticle%20albumin-bound%20paclitaxel%20with%20or%20without%20CC-486%20as%20second-line%20treatment%20for%20advanced%20nonsquamous%20non-small%20cell%20lung%20cancer%20(NSCLC).%20Cancer.%202018;124(24):4667%E2%80%9375." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR134">
<span class="label">134.</span><cite>Fillmore CM, Xu C, Desai PT, et al. Author correction: EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors. Nature. 2018;563(7732):E27.
</cite> [<a href="https://doi.org/10.1038/s41586-018-0580-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30250255/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Fillmore%20CM,%20Xu%20C,%20Desai%20PT,%20et%20al.%20Author%20correction:%20EZH2%20inhibition%20sensitizes%20BRG1%20and%20EGFR%20mutant%20lung%20tumours%20to%20TopoII%20inhibitors.%20Nature.%202018;563(7732):E27." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR135">
<span class="label">135.</span><cite>Ramalingam SS, Maitland ML, Frankel P, et al. Carboplatin and paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J Clin Oncol. 2010;28(1):56–62.
</cite> [<a href="https://doi.org/10.1200/JCO.2009.24.9094" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2799233/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19933908/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ramalingam%20SS,%20Maitland%20ML,%20Frankel%20P,%20et%20al.%20Carboplatin%20and%20paclitaxel%20in%20combination%20with%20either%20vorinostat%20or%20placebo%20for%20first-line%20therapy%20of%20advanced%20non-small-cell%20lung%20cancer.%20J%20Clin%20Oncol.%202010;28(1):56%E2%80%9362." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR136">
<span class="label">136.</span><cite>Crabb SJ, Danson S, Catto JWF, et al. Phase I trial of DNA methyltransferase inhibitor guadecitabine combined with cisplatin and gemcitabine for solid malignancies including urothelial carcinoma (SPIRE). Clin Cancer Res. 2021;27(7):1882–92.
</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-20-3946" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7611191/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33472913/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Crabb%20SJ,%20Danson%20S,%20Catto%20JWF,%20et%20al.%20Phase%20I%20trial%20of%20DNA%20methyltransferase%20inhibitor%20guadecitabine%20combined%20with%20cisplatin%20and%20gemcitabine%20for%20solid%20malignancies%20including%20urothelial%20carcinoma%20(SPIRE).%20Clin%20Cancer%20Res.%202021;27(7):1882%E2%80%9392." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR137">
<span class="label">137.</span><cite>Shi MQ, Xu Y, Fu X, et al. Advances in targeting histone deacetylase for treatment of solid tumors. J Hematol Oncol. 2024;17(1):37.
</cite> [<a href="https://doi.org/10.1186/s13045-024-01551-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11143662/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38822399/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Shi%20MQ,%20Xu%20Y,%20Fu%20X,%20et%20al.%20Advances%20in%20targeting%20histone%20deacetylase%20for%20treatment%20of%20solid%20tumors.%20J%20Hematol%20Oncol.%202024;17(1):37." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR138">
<span class="label">138.</span><cite>Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer. 2012;12(5):323–34.
</cite> [<a href="https://doi.org/10.1038/nrc3261" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22513401/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Marusyk%20A,%20Almendro%20V,%20Polyak%20K.%20Intra-tumour%20heterogeneity:%20a%20looking%20glass%20for%20cancer?%20Nat%20Rev%20Cancer.%202012;12(5):323%E2%80%9334." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR139">
<span class="label">139.</span><cite>Wen J, Fu J, Zhang W, Guo M. Genetic and epigenetic changes in lung carcinoma and their clinical implications. Mod Pathol. 2011;24(7):932–43.
</cite> [<a href="https://doi.org/10.1038/modpathol.2011.46" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21423157/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wen%20J,%20Fu%20J,%20Zhang%20W,%20Guo%20M.%20Genetic%20and%20epigenetic%20changes%20in%20lung%20carcinoma%20and%20their%20clinical%20implications.%20Mod%20Pathol.%202011;24(7):932%E2%80%9343." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR140">
<span class="label">140.</span><cite>Rothschild SI. Epigenetic therapy in lung cancer - role of microRNAs. Front Oncol. 2013;3:158.
</cite> [<a href="https://doi.org/10.3389/fonc.2013.00158" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3685817/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23802096/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Rothschild%20SI.%20Epigenetic%20therapy%20in%20lung%20cancer%20-%20role%20of%20microRNAs.%20Front%20Oncol.%202013;3:158." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR141">
<span class="label">141.</span><cite>Pérez-Ramírez C, Cañadas-Garre M, Molina MÁ, Faus-Dáder MJ, Calleja-Hernández MÁ. PTEN and PI3K/AKT in non-small-cell lung cancer. Pharmacogenomics. 2015;16(16):1843–62.
</cite> [<a href="https://doi.org/10.2217/pgs.15.122" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26555006/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?P%C3%A9rez-Ram%C3%ADrez%20C,%20Ca%C3%B1adas-Garre%20M,%20Molina%20M%C3%81,%20Faus-D%C3%A1der%20MJ,%20Calleja-Hern%C3%A1ndez%20M%C3%81.%20PTEN%20and%20PI3K/AKT%20in%20non-small-cell%20lung%20cancer.%20Pharmacogenomics.%202015;16(16):1843%E2%80%9362." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR142">
<span class="label">142.</span><cite>Xu M, Deng X, Xiang N, Zhang Z, Yang M, Liu Q. Plk3 enhances Cisplatin sensitivity of nonsmall-cell lung cancer cells through inhibition of the PI3K/AKT pathway via stabilizing PTEN. ACS Omega. 2024;9(8):8995–9002.
</cite> [<a href="https://doi.org/10.1021/acsomega.3c07271" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10905570/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38434880/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Xu%20M,%20Deng%20X,%20Xiang%20N,%20Zhang%20Z,%20Yang%20M,%20Liu%20Q.%20Plk3%20enhances%20Cisplatin%20sensitivity%20of%20nonsmall-cell%20lung%20cancer%20cells%20through%20inhibition%20of%20the%20PI3K/AKT%20pathway%20via%20stabilizing%20PTEN.%20ACS%20Omega.%202024;9(8):8995%E2%80%939002." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR143">
<span class="label">143.</span><cite>Zhao J, Xue X, Fu W, et al. Epigenetic activation of FOXF1 confers cancer stem cell properties to cisplatin-resistant non-small cell lung cancer. Int J Oncol. 2020;56(5):1083–92.
</cite> [<a href="https://doi.org/10.3892/ijo.2020.5003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7115358/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32319573/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhao%20J,%20Xue%20X,%20Fu%20W,%20et%20al.%20Epigenetic%20activation%20of%20FOXF1%20confers%20cancer%20stem%20cell%20properties%20to%20cisplatin-resistant%20non-small%20cell%20lung%20cancer.%20Int%20J%20Oncol.%202020;56(5):1083%E2%80%9392." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR144">
<span class="label">144.</span><cite>Kong W, Ling X, Chen Y, et al. Hesperetin reverses P-glycoprotein-mediated cisplatin resistance in DDP-resistant human lung cancer cells via modulation of the nuclear factor-κB signaling pathway. Int J Mol Med. 2020;45(4):1213–24.
</cite> [<a href="https://doi.org/10.3892/ijmm.2020.4485" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7053858/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32124932/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kong%20W,%20Ling%20X,%20Chen%20Y,%20et%20al.%20Hesperetin%20reverses%20P-glycoprotein-mediated%20cisplatin%20resistance%20in%20DDP-resistant%20human%20lung%20cancer%20cells%20via%20modulation%20of%20the%20nuclear%20factor-%CE%BAB%20signaling%20pathway.%20Int%20J%20Mol%20Med.%202020;45(4):1213%E2%80%9324." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>Not applicable.</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Clinical Epigenetics are provided here courtesy of <strong>BMC</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1186/s13148-025-01961-6"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/13148_2025_Article_1961.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (1.2 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12376372/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12376372/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12376372%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12376372/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12376372/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12376372/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40851017/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12376372/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40851017/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12376372/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12376372/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="2KT3WkkFNsPNCyb7hQc8d0cxLN3UBzHJk2a4lNdHvtIBhpQqhxi9m67V6vcE7NZY">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
